var title_f23_12_23744="Melanoma small bowel SBFT";
var content_f23_12_23744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melanoma of the small bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through study shows multiple rounded, nodular filling defects in the wall of the small bowel (arrows). Multiple small bowel tumors may be seen in metastatic disease or in polyposis syndromes; the most common cause of small bowel metastases is melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23744=[""].join("\n");
var outline_f23_12_23744=null;
var title_f23_12_23745="Fibromyalgia SPECT scans";
var content_f23_12_23745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F71376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F71376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain SPECT scan from a fibromyalgia patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images in (A) transverse, (B) coronal, and (C) sagittal section during the resting state. There is low blood flow to the caudate head nucleus (C) compared to the normal control (compare A to Figure 9A). There is also slightly decreased blood flow to the thalamus compared to the normal control. (D, E, F) Same fibromyalgia patient and same corresponding SPECT sections during pain stimulation. The fibromyalgia patient was stimulated on the right side of the body in the shoulder and sternoclavicular regions. During pain stimulation there is slight increased blood flow to the left thalamus (D), which is relatively less than was seen during stimulation of the normal control subject (Figure 9D). There was also a greater increase in blood flow to the somatosensory cortex (SS cortex) shown in E, and cingulate gyrus shown in F, compared to the normal control shown in Figures 9E and 9F, respectively. These abnormal patterns of change in blood flow correlate with recent hypotheses concerning disregulatory neuronal pathways involving the thalamus and the cingulate cortex during pain stimulation in fibromyalgia syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mountz JM, Bradley LA, Alarc&oacute;n GS. Abnormal functional activity of the central nervous system in fibromyalgia syndrome. Am J Med Sci 1998; 315:385. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23745=[""].join("\n");
var outline_f23_12_23745=null;
var title_f23_12_23746="Patient information: Chronic pain (The Basics)";
var content_f23_12_23746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/33/25105\">",
"         Patient information: Alternative medicine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/20/43329\">",
"         Patient information: Fibromyalgia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/6/11363\">",
"         Patient information: Narcotic pain medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/42/8867\">",
"         Patient information: Neuropathic pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic pain (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-pain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30614058\">",
"      <span class=\"h1\">",
"       What is chronic pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic pain is pain that lasts longer than 3 months. In many cases, this means that pain continues even after the injury or condition that first caused it has been treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614073\">",
"      <span class=\"h1\">",
"       What causes chronic pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The cause of chronic pain is not always clear. Sometimes it is caused by an ongoing medical problem, such as arthritis or diabetic neuropathy (a form of nerve damage from diabetes). But doctors cannot always find the cause of chronic pain.",
"     </p>",
"     <p>",
"      In some cases, people with chronic pain must accept that their pain will never be explained. This does not mean that they have to accept their pain. It just means that they have to work with their healthcare team to address the pain, even if they don&rsquo;t know its cause.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614088\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of chronic pain is, of course, pain. But the pain can affect the body in different ways. Some people have aches deep inside their muscle or bone. Some people have stabbing or shooting pain, often with tingling or numbness. And others have dull, throbbing pain.",
"     </p>",
"     <p>",
"      People who have chronic pain might have a hard time doing their usual activities, such as bathing or dressing. This can lead to depression and anxiety, and it can cause problems with sleep.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614103\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you first start having pain, your doctor might do tests to figure out the cause. You might have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests to check for infection or signs of inflammation",
"       </li>",
"       <li>",
"        X-rays or other imaging tests to check for bone fractures, joint damage, cancer, or other changes in your body that could cause pain",
"       </li>",
"       <li>",
"        Nerve tests to check whether the nerves are working normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Once you have had these tests, your doctor probably won&rsquo;t do any others. That&rsquo;s because tests cannot always show the cause of pain. Scientists think that in some people, the pain signals in the brain stop working normally. The signals get &ldquo;stuck&rdquo; in the on position, even when the source of pain is gone.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614118\">",
"      <span class=\"h1\">",
"       How is chronic pain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments for chronic pain include both medicines and activities. No single treatment works for everyone. Your doctor or nurse will help you find the right mix of treatments for you. Treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to relieve pain, improve sleep, or improve mood",
"       </li>",
"       <li>",
"        Physical therapy to learn exercises and stretches",
"       </li>",
"       <li>",
"        Working with a counselor",
"       </li>",
"       <li>",
"        Relaxation therapy",
"       </li>",
"       <li>",
"        Massage therapy",
"       </li>",
"       <li>",
"        Injections (shots) of numbing or pain-relieving medicines into the spine or area with pain",
"       </li>",
"       <li>",
"        Acupuncture",
"       </li>",
"       <li>",
"        Devices that affect nerve signals",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To find the best treatment for you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Be open to trying new treatments and combinations of treatments. Sometimes you have to try a few different options before you find one that works best.",
"       </li>",
"       <li>",
"        Set realistic goals for your treatment. Even if you can&rsquo;t completely get rid of your pain, you might be able to control it enough so that you can do the things you want to do.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your doctor suggests a medicine that seems out of place, keep an open mind. Sometimes, doctors treat pain with medicines made to treat other medical problems. For example, doctors can use medicines for depression to treat pain because they work on areas of the brain that process pain. Doctors can also use medicines for seizures to treat pain, because they help with overactive nerves.",
"     </p>",
"     <p>",
"      Keep in mind, too, that many people need a team to help manage their care. A treatment team usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Doctors or specialists",
"       </li>",
"       <li>",
"        A physical therapist",
"       </li>",
"       <li>",
"        Someone trained in mental health (such as a social worker or counselor)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614133\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some things to try include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use a heating pad or a cold pack on the painful area. Check with your doctor before trying this to make sure it is OK for your individual condition.",
"       </li>",
"       <li>",
"        Practice relaxing. You can learn methods to relax your body, such as doing deep breathing exercises. Ask your doctor or nurse about these methods. Relaxing the mind can help with how the body feels pain. People can learn to quiet their pain or make it less bothersome.",
"       </li>",
"       <li>",
"        Stay as active as possible. Walking, swimming, tai chi (a kind of martial art), or biking can all help ease muscle and joint pain. If you are not active, your pain might get worse.",
"        <br/>",
"        <br/>",
"        If you haven&rsquo;t been active for a while, start slowly. Make small increases in the intensity and amount of time you spend exercising. If exercising increases your pain, talk with your doctor. He or she might recommend a program that can help you get more active.",
"       </li>",
"       <li>",
"        If you feel depressed, talk to your doctor or nurse about it. Chronic pain and depression often go together, and each can make the other worse. Getting treatment for your depression can make it easier to cope with your pain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30614148\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=see_link\">",
"       Patient information: Alternative medicine (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=see_link\">",
"       Patient information: Fibromyalgia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=see_link\">",
"       Patient information: Neuropathic pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=see_link\">",
"       Patient information: Narcotic pain medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/12/23746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16981 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23746=[""].join("\n");
var outline_f23_12_23746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614058\">",
"      What is chronic pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614073\">",
"      What causes chronic pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614088\">",
"      What are the symptoms of chronic pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614103\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614118\">",
"      How is chronic pain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614133\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30614148\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=related_link\">",
"      Patient information: Fibromyalgia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=related_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23747="Patient information: Uterine cancer (The Basics)";
var content_f23_12_23747=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15422\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"          Types of abdominal hysterectomy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/49/20243\">",
"           Vaginal hysterectomy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/25/14738\">",
"         Patient information: Heavy periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/27/40370\">",
"         Patient information: Menopause (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/18/22820\">",
"         Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/24/8578\">",
"         Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/55/19314\">",
"         Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/12/8388\">",
"         Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7537\">",
"         Patient information: Vaginal dryness (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/48/34564\">",
"         Patient information: Vaginal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Uterine cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/uterine-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1666148368\">",
"      <span class=\"h1\">",
"       What is uterine cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Uterine cancer happens when normal cells in the uterus change into abnormal cells and grow out of control. The uterus (also called the womb) is the part of a woman&rsquo;s body that holds a baby if she is pregnant. The uterus has a thin inner lining layer and a thick outer layer (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are different types of uterine cancer, but most uterine cancer starts in cells in the thin inner lining. Uterine cancer can occur in women of any age, but is much more common in women who have gone through menopause. Menopause is the time in a woman&rsquo;s life when she stops having menstrual periods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148375\">",
"      <span class=\"h1\">",
"       What are the symptoms of uterine cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom of uterine cancer is abnormal vaginal bleeding. Abnormal vaginal bleeding includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding in between menstrual cycles (at times other than during your period)",
"       </li>",
"       <li>",
"        Menstrual bleeding that is heavier than usual",
"       </li>",
"       <li>",
"        Any vaginal bleeding in a woman who has already gone through menopause",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can be caused by conditions that are not cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148382\">",
"      <span class=\"h1\">",
"       Is there a test for uterine cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have abnormal vaginal bleeding, your doctor or nurse might order a test called a biopsy to check for uterine cancer. During a biopsy, a doctor takes a small sample of tissue from the uterine lining. Doctors can do biopsies in different ways. Another doctor will look at the sample under a microscope to see if cancer is present.",
"     </p>",
"     <p>",
"      Women who have gone through menopause can also have an imaging test called an ultrasound to check for uterine cancer. This test measures how thick the uterine lining is.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148389\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far the cancer has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your cancer and how fast it is growing. Your treatment will also depend on your age and other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148396\">",
"      <span class=\"h1\">",
"       How is uterine cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women with uterine cancer have surgery to remove the uterus, ovaries, and the tubes connecting the ovaries to the uterus (fallopian tubes). This surgery is called a &ldquo;hysterectomy&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef57901 \" href=\"UTD.htm?37/40/38534\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71521 \" href=\"UTD.htm?19/49/20243\">",
"       figure 3",
"      </a>",
"      ). During surgery, the doctor will also check the area and organs around the uterus to see if the cancer has spread. He or she might remove other organs that look abnormal.",
"     </p>",
"     <p>",
"      Some women will not need further treatment after surgery if surgery removes the cancer. But other women might need further treatment with one or both of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells. Radiation can be given from a machine that is outside the body. Or a doctor can put a source of radiation directly into the vagina.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148403\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Regular follow up tests include exams and Pap tests. During a Pap test, a doctor or nurse props open the walls of the vagina using a device that looks like a duck beak (called a speculum). He or she then uses a small brush to collect cells from the cervix. Other follow-up tests can include blood tests and imaging tests such as X-rays.",
"     </p>",
"     <p>",
"      You should also watch for symptoms of abnormal vaginal bleeding, pain in your belly, or a cough that won&rsquo;t go away. Let your doctor or nurse know if you have these symptoms. They could mean your cancer has come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148410\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery, radiation therapy, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148417\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant one day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not yet gone through menopause and want to have a baby one day, talk with your doctor. A woman cannot get pregnant after a hysterectomy or radiation. Your doctor can discuss different options with you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148424\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for uterine cancer involves making many choices, such as what treatment to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1666148431\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       Patient information: Menopause (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       Patient information: Heavy periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"       Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"       Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"       Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"       Patient information: Vaginal hysterectomy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"       Patient information: Vaginal dryness (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/12/23747?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15422 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23747=[""].join("\n");
var outline_f23_12_23747=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148368\">",
"      What is uterine cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148375\">",
"      What are the symptoms of uterine cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148382\">",
"      Is there a test for uterine cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148389\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148396\">",
"      How is uterine cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148403\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148410\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148417\">",
"      What if I want to get pregnant one day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148424\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666148431\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"       Types of abdominal hysterectomy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/49/20243\">",
"        Vaginal hysterectomy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=related_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=related_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=related_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23748="SLE pulmonary fibrosis PA";
var content_f23_12_23748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interstitial lung disease with systemic lupus erythematosus (SLE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Systemic lupus erythematosus (SLE) with bibasilar pulmonary fibrosis producing loss of volume and partial obscuration of the diaphragmatic contour.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23748=[""].join("\n");
var outline_f23_12_23748=null;
var title_f23_12_23749="Ramipril: Patient drug information";
var content_f23_12_23749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ramipril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     see \"Ramipril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg;;",
"     </li>",
"     <li>",
"      Apo-Ramipril&reg;;",
"     </li>",
"     <li>",
"      Ava-Ramipril;",
"     </li>",
"     <li>",
"      CO Ramipril;",
"     </li>",
"     <li>",
"      Dom-Ramipril;",
"     </li>",
"     <li>",
"      JAMP-Ramipril;",
"     </li>",
"     <li>",
"      Mylan-Ramipril;",
"     </li>",
"     <li>",
"      PHL-Ramipril;",
"     </li>",
"     <li>",
"      PMS-Ramipril;",
"     </li>",
"     <li>",
"      RAN&trade;-Ramipril;",
"     </li>",
"     <li>",
"      ratio-Ramipril;",
"     </li>",
"     <li>",
"      Sandoz-Ramipril;",
"     </li>",
"     <li>",
"      Teva-Ramipril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702850",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ramipril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2996279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce or in apple juice. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696478",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more often than every 12 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11018 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23749=[""].join("\n");
var outline_f23_12_23749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217165\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217166\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020761\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020763\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020762\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020767\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020768\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020770\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020765\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020766\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020771\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020772\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=related_link\">",
"      Ramipril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23750="CT appendicitis in pregnancy";
var content_f23_12_23750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    CT appendicitis in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The main findings of appendicitis on computed tomography (CT) are right lower quadrant inflammation, an enlarged nonfilling tubular structure, and/or an appendicolith.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joel Goldberg, MD, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23750=[""].join("\n");
var outline_f23_12_23750=null;
var title_f23_12_23751="Peripheral IV catheters";
var content_f23_12_23751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peripheral IV catheters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows two Becton-Dickinson&trade; Autoguard&trade; catheter-over-needle intravenous catheters with retractable safety needles. The pink catheter is 20 guage and the green is 18 guage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23751=[""].join("\n");
var outline_f23_12_23751=null;
var title_f23_12_23752="Management of inherited thrombophilia";
var content_f23_12_23752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of inherited thrombophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23752/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/12/23752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. Factor V Leiden is the most common cause of the syndrome, accounting for 40 to 50 percent of cases. The prothrombin gene mutation, deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/1\">",
"     1",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management issues related to thromboembolism in patients with inherited thrombophilia are reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial management of acute thromboembolic disease in patients with inherited risk factors for thrombosis is not different from that in other patients. Less well established is the long-term management of patients with inherited thrombophilia who have had venous thrombosis and of patients exposed to the increased risk associated with pregnancy and surgery. In most cases, randomized prospective studies have not been performed, and only general guidelines are available for the clinician taking care of these patients.",
"   </p>",
"   <p>",
"    The usefulness of screening for these conditions in various asymptomatic populations and the value of screening in patients presenting with thrombosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the management of pregnant women with inherited thrombophilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual initial treatment of acute venous thromboembolism consists of unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low-molecular-weight heparin followed by anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for three to six months. Warfarin can be started within the first 24 hours. Heparin or low molecular weight heparin is continued for at least five days and until the prothrombin time has been in the therapeutic range (ie, INR of 2.0 to 3.0) for at least two days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Initial anticoagulation regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During this initial period of anticoagulation, special consideration may need to be given to selected patients known to have hereditary antithrombin or protein C deficiency, as discussed below. Routine measurement of plasma antithrombin or protein C concentrations in all individuals presenting with thrombosis is not recommended.",
"   </p>",
"   <p>",
"    While recurrence of VTE may occur in all patients with idiopathic VTE in whom anticoagulation has been stopped, whether or not a hypercoagulable state is present, the risk of recurrence is not increased in patients with a hypercoagulable state during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . This was shown in a retrospective review of the ELATE trial, in which one or more thrombophilic defects were present in 42 percent of the participants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/3\">",
"     3",
"    </a>",
"    ]. The overall rate of recurrent VTE WHILE TAKING WARFARIN was 0.9 percent, and was not increased in the presence of one, or more than one, thrombophilic defects (eg, factor V Leiden, the G20210A prothrombin gene mutation, antithrombin deficiency, or elevation in factor VIII, factor XI, or homocysteine). There was a trend to an increased rate of recurrence in those with antiphospholipid antibodies (HR 2.9; 95% CI 0.8-10). The rate of recurrence while taking warfarin was not increased in the presence or one, or more than one, thrombophilic defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antithrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with deficiency of antithrombin (AT, formerly known as ATIII) are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and require large doses. This is in part due to the action of heparin to further lower AT levels by approximately 30 percent. Antithrombin concentrate has been used safely and effectively in patients with AT deficiency and acute venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Use of this concentrate is recommended in those patients who have unusually severe thrombosis, develop recurrent thrombosis despite adequate anticoagulation, or have difficulty achieving adequate anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AT concentrate (Thrombate III&reg;) is prepared from pooled normal human plasma. The manufacturing process results in a product that is 95 percent pure and inactivates hepatitis B virus and the human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. It can be administered over a 10 to 20 minute period. One unit is defined as the amount of AT in one mL of pooled normal human plasma. Recovery in vivo in patients with AT deficiency is 1.4 to 2.7",
"    <span class=\"nowrap\">",
"     percent/unit",
"    </span>",
"    per kg [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Recovery is lower in patients with acute thrombotic events and those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/5\">",
"     5",
"    </a>",
"    ]. The biologic half-life is approximately 2.8 to 4.8 days.",
"   </p>",
"   <p>",
"    The recommended INITIAL dose of AT (in units) is calculated as follows:",
"   </p>",
"   <p>",
"    &nbsp;[desired AT level (%) - baseline level (%) ] x weight (kg) &divide; 1.4",
"   </p>",
"   <p>",
"    Thus, the infusion of 50 units of AT concentrate per kilogram of body weight will usually raise the plasma AT level to approximately 120 percent in a congenitally deficient individual with a baseline value of 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. Plasma levels should be monitored to ensure that they remain above 80 percent; the administration of 60 percent of the initial dose at 24-hour intervals is recommended to maintain AT levels in the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of AT concentrate as adjunctive therapy in patients with AT deficiency and venous thromboembolism has not been studied in a controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A recombinant human antithrombin, produced from the milk of transgenic goats, is now available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H25#H25\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Antithrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protein C deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary protein C deficiency can be associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis. The initiation of warfarin at standard doses leads to a decrease in protein C anticoagulant activity to approximately 50 percent of normal within one day. Factor VII activity follows a similar pattern but the levels of the other procoagulant vitamin K-dependent factors decline at slower rates, consistent with their longer half-lives [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/13\">",
"     13",
"    </a>",
"    ]. The suppressive effect of warfarin on protein C appears to have a greater influence on thrombin generation by the hemostatic mechanism than the associated reduction in factor VII, resulting in a transient hypercoagulable state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the risk of a transient hypercoagulable state in protein C-deficient patients during initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , routine measurement of plasma protein C concentrations in all individuals with thrombosis before the initiation of oral anticoagulants is not recommended. There are three observations underlying this conclusion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The frequency of asymptomatic hereditary protein C deficiency is relatively high (eg, one in 200 in a report of healthy blood donors) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The occurrence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis among patients with protein C deficiency is infrequent",
"     </li>",
"     <li>",
"      There is difficulty in making a rapid and definitive laboratory diagnosis of the protein C deficiency state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Oral anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral anticoagulation in a patient who is known or likely (eg, first-degree relative of a patient with protein C deficiency or a past history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis) to be protein C deficient should be started under the cover of full heparinization, with documentation of a therapeutic aPTT level or anti-Xa assay before starting warfarin. The dose of warfarin should be increased gradually, starting from a relatively low dose (eg, 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first three days) and then in slowly increasing amounts until therapeutic anticoagulation is achieved.",
"   </p>",
"   <p>",
"    Patients with heterozygous protein C deficiency and a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis have been successfully retreated with oral anticoagulants. Protein C administration, generally in the form of fresh frozen plasma or, less often,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    , provides protection against recurrent skin necrosis until a stable level of anticoagulation is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LONG-TERM THERAPY TO PREVENT RECURRENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Minimum period of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increased risk of recurrence, patients with unprovoked venous thromboembolism and an inherited thrombophilia are usually continued on oral anticoagulants for a minimum of three to six months at an INR of 2.0 to 3.0. Treatment following this period of time is dependent upon the number of recurrences, the number of thrombophilic defects found (eg, homozygosity or compound heterozygosity for a thrombophilic defect), as well as patient preferences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A complicating issue in the individual patient is that the risk of venous thromboembolism is not uniform in the different inherited thrombophilias. This was illustrated in a report that compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin, protein C, or protein S deficiency in 150 pedigrees [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/17\">",
"     17",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers (the vast majority were heterozygotes) of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H4#H4\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Causes and prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of chronic anticoagulation in high-risk patients was addressed in a controlled trial which evaluated the efficacy of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (INR 2 to 2.85) for six months or indefinitely in 227 patients with a second venous thrombotic episode, but not specifically inherited thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/18\">",
"     18",
"    </a>",
"    ]. Long-term warfarin was highly effective in preventing recurrences as compared to six months of therapy (2.6 versus 21 percent over four years); this benefit was partially counterbalanced by a trend toward an increased incidence of major hemorrhage (8.6 versus 2.3 percent). There was no difference in mortality between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the relatively high frequency (12 to 21 percent) of heterozygous factor V Leiden mutation in patients with a first episode of venous thrombosis, there is a substantial amount of data on the risk of recurrence. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H16#H16\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Combined inherited defects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H2406396#H2406396\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Risk of recurrent DVT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients in whom the first episode of DVT was spontaneous (idiopathic), the preponderance of evidence is that there is no difference in the incidence of recurrence, when anticoagulation is stopped, between those with or without factor V Leiden, except if they have more than one thrombophilic defect (eg, heterozygous for the prothrombin gene mutation as well as factor V Leiden).",
"   </p>",
"   <p>",
"    Although carefully controlled studies of recurrence rate are not available for the other causes of thrombophilia, most clinicians with experience in managing patients with these disorders feel that patients with type I congenital AT deficiency have a recurrence rate which exceeds all of the other causes of inherited thrombophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombin (ATIII) deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Argument against long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies argue against the use of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy after a first thromboembolic episode in patients with inherited thrombophilia. As an example, the recurrence rate after discontinuation of oral anticoagulant therapy was assessed in 62 patients with factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, as well as in the ELATE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/3\">",
"     3",
"    </a>",
"    ], none of the patients had a recurrent event while taking warfarin. The median time to recurrence after stopping warfarin was nine years; the period was shorter (3.5 years) among patients who suffered an idiopathic rather than precipitated first event. It was estimated that, even in the former group, death from hemorrhage would probably exceed the number of fatal pulmonary emboli prevented with chronic warfarin therapy.",
"   </p>",
"   <p>",
"    Among patients enrolled in the Leiden Thrombophilia Study who sustained a first idiopathic DVT, the risk of recurrent venous thrombosis in those with inherited thrombophilia",
"    <span class=\"nowrap\">",
"     (3.4/100",
"    </span>",
"    patient-years) was similar to those without an underlying thrombophilic defect",
"    <span class=\"nowrap\">",
"     (3.2/100",
"    </span>",
"    patient-years, HR 1.2; 95% CI 0.7-2.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision analysis model concerning the value of extended anticoagulation in patients with factor V Leiden who had a first deep vein thrombosis concluded that the number of major induced hemorrhages would exceed the number of clinical pulmonary emboli that would be prevented, and that extension of oral anticoagulation beyond one year would not produce clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other studies were unable to demonstrate an increase in mortality in patients with factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/22\">",
"     22",
"    </a>",
"    ], protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/23\">",
"     23",
"    </a>",
"    ], and AT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], further supporting the argument that the mortality risk of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy in the asymptomatic thrombophilic patient exceeds the potential benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, we suggest indefinite anticoagulation only in the following high-risk patients with hereditary thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two or more spontaneous thromboses or one spontaneous thrombosis in the case of antithrombin deficiency or the antiphospholipid syndrome",
"     </li>",
"     <li>",
"      One spontaneous life-threatening thrombosis (eg, near-fatal pulmonary embolism; cerebral, mesenteric, or portal vein thrombosis)",
"     </li>",
"     <li>",
"      One spontaneous thrombosis at an unusual site (eg, mesenteric or cerebral vein)",
"     </li>",
"     <li>",
"      One spontaneous thrombosis in the presence of more than a single genetic defect predisposing to a thromboembolic event (eg, combined heterozygosity for protein S deficiency, protein C deficiency, or antithrombin deficiency) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16941572\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the pregnant patient with inherited thrombophilia is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inherited thrombophilia who undergo surgery should generally be treated as a high-risk group and receive prophylactic doses of anticoagulation with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or unfractionated heparin; this is especially true for patients with a prior personal history of venous thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Surgical risk groups'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link&amp;anchor=H8#H8\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H19#H19\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterozygosity for the factor V Leiden mutation is generally associated with a lower risk for a first venous thrombotic event than the anticoagulant protein deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/17\">",
"     17",
"    </a>",
"    ]. Some data indicate that previously asymptomatic patients undergoing major orthopedic surgery may not have a higher than usual thrombotic risk, but these were largely asymptomatic clots detected by venography of the legs within the context of clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We would therefore recommend that",
"    <strong>",
"     heterozygotes",
"    </strong>",
"    for the factor V Leiden mutation be considered for prophylactic anticoagulation based upon the degree of risk associated with the surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their underlying medical condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H30#H30\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factor V Leiden",
"    <strong>",
"     homozygotes",
"    </strong>",
"    undergoing surgery should be managed as a higher risk group in the perioperative setting, even in the absence of a personal thrombosis history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H30#H30\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     AT deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is associated with a reduction in AT levels for three to five days postoperatively and some patients with AT deficiency and low concentrations of AT may not respond well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . For this reason, and to reduce the threat of bleeding from anticoagulation, AT concentrates have been used successfully in several case reports and studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/5,30,31\">",
"     5,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a retrospective study evaluated the outcome in 23 patients with congenital AT deficiency who underwent 57 operations of various types [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/30\">",
"     30",
"    </a>",
"    ]. Thromboprophylaxis was given in 28 operations;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    was used in most cases, sometimes in combination with a specific AT concentrate. No patient given AT concentrate alone or in combination with other methods had signs of thromboembolism. In contrast, deep vein thrombosis occurred after surgery in 17 percent of patients who received no prophylaxis and in 22 percent of procedures in which another form of prophylaxis, usually dextran, was used.",
"   </p>",
"   <p>",
"    A recombinant human antithrombin has been developed using transgenic technology, and has gained approval for managing patients with AT deficiency undergoing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23752/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16941630\">",
"    <span class=\"h2\">",
"     Patients with no thrombosis history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals who are heterozygous for an inherited thrombophilia without clinical thrombosis are unlikely to be aware they have a genetic defect. Our general approach to the management of those with laboratory-only evidence of thrombophilia is to treat them as we do the general population (ie, we do not anticoagulate them prophylactically, save for high-risk settings such as major surgery). The rationale for this approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Arguments against screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Arguments in favor of screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases, an individual may present with laboratory evidence of homozygosity, compound heterozygosity for an inherited thrombophilia, or a single higher risk thrombophilic defect (eg, antithrombin deficiency) without a personal thrombosis history. There are no data that show a benefit of long term anticoagulation in these patients, and we generally do not anticoagulate them. However, anticoagulation might be appropriate for such an asymptomatic individual who places an especially high value on preventing thrombosis (eg, due to massive, unprovoked pulmonary embolism in a family member).",
"   </p>",
"   <p>",
"    Although we do not anticoagulate the vast majority of individuals with laboratory-only evidence of thrombophilia, there may be value in discussing the following issues (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H15692258#H15692258\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Summary'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Awareness of signs and symptoms of venous thromboembolism requiring prompt medical attention (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link&amp;anchor=H3#H3\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Initial approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Family history, both to clarify individual risk and to counsel regarding testing or not testing of family members (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H2#H2\">",
"       \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'General screening issues'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prophylactic anticoagulation during high risk situations (eg, pregnancy, surgery) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link&amp;anchor=H7898355#H7898355\">",
"       \"Inherited thrombophilias in pregnancy\", section on 'Prevention of VTE'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Potential avoidance of oral contraceptives (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=see_link&amp;anchor=H9#H9\">",
"       \"Contraception for women with inherited thrombophilias\", section on 'Use of combined hormonal contraception by women who have or may have a thrombophilia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link&amp;anchor=H12#H12\">",
"       \"Screening for inherited thrombophilia in asymptomatic populations\", section on 'Oral contraceptives'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16941745\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of children with inherited thrombophilia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=see_link\">",
"     \"Screening for inherited thrombophilia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       \"Patient information: Factor V Leiden (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the initial treatment of acute VTE, we recommend that patients with inherited thrombophilia receive standard initial treatment of acute venous thromboembolism (ie, unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low-molecular-weight heparin followed by anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H43#H43\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Initial anticoagulation regimen'",
"      </a>",
"      .) There are three exceptions to this recommendation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Use of an antithrombin concentrate is suggested in those patients with AT deficiency who have unusually severe thrombosis, develop recurrent thrombosis despite adequate anticoagulation, or have difficulty achieving adequate anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a patient who is known to be protein C deficient, we recommend that oral anticoagulation be started under the cover of full heparinization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should be low (eg, 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for the first three days) and then increased slowly until therapeutic anticoagulation is achieved. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Oral anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with heterozygous protein C deficiency and a history of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis, we suggest protein C administration, either in the form of fresh frozen plasma or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6949?source=see_link\">",
"       protein C concentrate",
"      </a>",
"      , to provide protection against recurrent skin necrosis until a stable level of anticoagulation with warfarin is achieved (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Oral anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with venous thromboembolism and an inherited thrombophilia continue on oral anticoagulants for a minimum of three to six months at an INR of 2.0 to 3.0 (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest indefinite anticoagulation only for high-risk patients with hereditary thrombophilia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'High-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For surgical prophylaxis, we suggest that most patients with inherited thrombophilia be treated as a high-risk group and receive prophylactic and postoperative anticoagulation with low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Surgical risk groups'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with AT deficiency undergoing major surgery, we also suggest the use of AT concentrates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'AT deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of the pregnant patient with inherited thrombophilia is discussed in depth separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"       \"Inherited thrombophilias in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/1\">",
"      Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/2\">",
"      Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/3\">",
"      Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112:4432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/4\">",
"      Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 1989; 87:53S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/5\">",
"      Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990; 75:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/6\">",
"      Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/7\">",
"      Hoffman DL. Purification and large-scale preparation of antithrombin III. Am J Med 1989; 87:23S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/8\">",
"      Mannucci PM, Boyer C, Wolf M, et al. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982; 50:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/9\">",
"      Winter JH, Fenech A, Bennett B, Douglas AS. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span. Br J Haematol 1981; 49:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/10\">",
"      Brandt P. Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res 1981; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/11\">",
"      Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/12\">",
"      Lechner K, Kyrle PA. Antithrombin III concentrates--are they clinically useful? Thromb Haemost 1995; 73:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/13\">",
"      Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/14\">",
"      Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/15\">",
"      Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/16\">",
"      De Stefano V, Mastrangelo S, Schwarz HP, et al. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/17\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/18\">",
"      Schulman S, Granqvist S, Holmstr&ouml;m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/19\">",
"      Baglin C, Brown K, Luddington R, Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. Br J Haematol 1998; 100:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/20\">",
"      Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/21\">",
"      Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 1998; 316:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/22\">",
"      Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/23\">",
"      Allaart CF, Rosendaal FR, Noteboom WM, et al. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ 1995; 311:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/24\">",
"      van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/25\">",
"      Rosendaal FR, Heijboer H, Bri&euml;t E, et al. Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet 1991; 337:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/26\">",
"      De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/27\">",
"      Marchetti M, Quaglini S, Barosi G. Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 2001; 94:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/28\">",
"      Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/29\">",
"      W&aring;hlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 2002; 87:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/30\">",
"      Tengborn L, Bergqvist D. Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand 1988; 154:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/31\">",
"      Jackson MR, Olsen SB, Gomez ER, Alving BM. Use of antithrombin III concentrates to correct antithrombin III deficiency during vascular surgery. J Vasc Surg 1995; 22:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23752/abstract/32\">",
"      Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1365 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23752=[""].join("\n");
var outline_f23_12_23752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antithrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LONG-TERM THERAPY TO PREVENT RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Minimum period of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Argument against long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16941572\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - AT deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16941630\">",
"      Patients with no thrombosis history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16941745\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=related_link\">",
"      Screening for inherited thrombophilia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23753="Musculoskeletal manifestations of systemic lupus erythematosus";
var content_f23_12_23753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Daniel J Wallace, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23753/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23753/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/12/23753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the musculoskeletal system is extremely common in patients with systemic lupus erythematosus (SLE). Arthralgia, arthritis, osteonecrosis (avascular necrosis of bone), and myopathy are the principal manifestations. Osteoporosis, often due to glucocorticoid therapy, may increase the risk of fractures.",
"   </p>",
"   <p>",
"    The musculoskeletal manifestations of SLE in adults are reviewed here. SLE in children and an overview of the clinical manifestations of SLE in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTHRITIS AND ARTHRALGIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis and arthralgias have been noted in up to 95 percent of patients with SLE. These symptoms may be mistaken for another type of inflammatory arthritis and can precede the diagnosis of SLE by months or years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritic symptoms in patients with SLE have the following characteristics that are generally different from those in rheumatoid arthritis (RA) (",
"    <a class=\"graphic graphic_table graphicRef54324 \" href=\"UTD.htm?23/47/24316\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arthritis and arthralgias of SLE tend to be migratory; symptoms in a particular joint may be gone within 24 hours.",
"     </li>",
"     <li>",
"      Involvement is usually symmetrical and polyarticular with a predilection for the knees, carpal joints, and joints of the fingers, especially the proximal interphalangeal (PIP) joint. The ankles, elbows, shoulders, and hips are less frequently involved. Involvement of the sacroiliac joints and cervical spine may occur but is rare. Monoarticular arthritis is unusual and suggests an alternative cause such as infection.",
"     </li>",
"     <li>",
"      Morning stiffness is usually measured in minutes and is not prolonged as in rheumatoid arthritis (RA).",
"     </li>",
"     <li>",
"      The degree of pain often exceeds objective physical findings, and tenderness may be difficult to assess because of increased pain sensitivity in some patients, which can be associated with coexisting fibromyalgia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the arthritis of SLE is generally considered to be nondeforming, flexion deformities, ulnar deviation, soft tissue laxity, and swan neck deformities, as seen in RA, have been noted in 15 to 50 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. However, unlike RA, erosions in the hand are rarely noted on plain radiographs of the hands in SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Similarly, in one study of 26 patients with SLE using ultrasonography, synovial proliferation and effusions were detected in the knees in 23 percent of patients, and synovitis was seen in 40 percent, although no erosions were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/8\">",
"     8",
"    </a>",
"    ]. More sensitive imaging methods, such as magnetic resonance imaging (MRI), more often reveal erosive changes and abnormalities of the soft tissues, including capsular swelling, proliferative tenosynovitis, and synovial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of antibodies to citrullinated",
"    <span class=\"nowrap\">",
"     peptides/proteins",
"    </span>",
"    (anti-CCP) antibodies (prevalent in 8 percent of patients with SLE) is strongly associated with erosive arthritis (odds ratio of 23 for anti-CCP positive versus negative patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hand deformity tends to occur in patients who have been receiving glucocorticoids, who have anti-Ro",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-La antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/5\">",
"     5",
"    </a>",
"    ], or who have longstanding disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast to the typical findings in RA, these deformities are usually easily reducible; they are thought to be due to lax joint capsules, tendons, and ligaments that cause joint instability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the hand deformities in patients with SLE resemble Jaccoud&rsquo;s arthritis, a nonerosive chronic deforming arthritis that may follow acute rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tendons may also be involved in SLE. Tenosynovitis has been noted in 10 to 44 percent of patients, including epicondylitis, rotator cuff tendinitis, Achilles tendinitis, tibialis posterior tendinitis, and plantar fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/4,6,12,13\">",
"     4,6,12,13",
"    </a>",
"    ]. Infrapatellar and Achilles tendon ruptures are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1030?source=see_link\">",
"     \"Posterior and medial ankle tendinopathies not involving the Achilles tendon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H370426595\">",
"    <span class=\"h2\">",
"     Synovial involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial effusions are infrequent in patients with SLE. When they occur, they are usually small, and the fluid is clear or slightly cloudy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast to the highly inflammatory exudates of RA, the synovial fluid is only mildly inflammatory, with low protein levels and white blood cell counts (similar to a transudate) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/4\">",
"     4",
"    </a>",
"    ]. Antinuclear antibodies (ANA) and lupus erythematosus (LE) cells have been observed in synovial fluids and, if present, have been thought to be useful diagnostically. However, they add little to a positive ANA in the serum.",
"   </p>",
"   <p>",
"    Synovial histopathology tends to be nonspecific, with superficial fibrin-like material and local or diffuse lining cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/4\">",
"     4",
"    </a>",
"    ]. Vascular changes have included perivascular mononuclear cells, lumen obliteration, enlarged endothelial cells, and thrombi; fibrinoid necrosis (eg, vasculitis) is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/16\">",
"     16",
"    </a>",
"    ]. Synovitis in SLE has a molecular synovial signature distinct from that seen in osteoarthritis or rheumatoid arthritis in that interferon-inducible genes are upregulated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septic bacterial arthritis is uncommon, although patients with SLE may be intrinsically immunosuppressed and may become more so with medication. When septic arthritis occurs, it can be secondary to infections with Salmonella, gonococci, meningococci, and other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs are available to treat the musculoskeletal pain associated with SLE. Nonsteroidal antiinflammatory drugs (NSAIDs) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is typically used first since the arthralgias and arthritis of SLE generally respond to these medications. Other drugs are added as necessary. Joint replacement surgery is only needed very infrequently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If inflammation (swelling, redness, warmth) is the most prominent feature, we favor NSAIDs rather than full-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (which requires too many pills). Typical doses are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (800 mg four times daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (500 mg twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"       nabumetone",
"      </a>",
"      (1 gram twice daily). In those at risk for NSAID-induced gastrointestinal toxicity, addition of a proton pump inhibitor (PPI) may be needed. The presence of lupus nephritis is a relative contraindication to the use of NSAIDs or selective COX-2 inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"       \"Overview of selective COX-2 inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If patients are complaining mostly of pain, we favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (up to 3",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in the absence of liver disease or alcoholism).",
"     </li>",
"     <li>",
"      Antimalarial drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ) are very effective for the amelioration of joint symptoms and for the prevention of clinical relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Hydroxychloroquine (Plaquenil) is typically given to patients with articular manifestations (usually added to an NSAID in a nonresponder), rashes, and fatigue. The dose of hydroxychloroquine is 200 to 400",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      the maximum dose is 6.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      to avoid ocular toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids are needed infrequently and should be avoided for the treatment of pain not associated with inflammation. In patients who have already been treated with glucocorticoids with a positive response, we start the patient on an NSAID and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      and taper the glucocorticoid.",
"     </li>",
"     <li>",
"      For resistant inflammatory arthritis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (initial dose 7.5",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      with increasing doses at monthly intervals as tolerated) has been shown to be useful [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. One prospective study, for example, investigated 12 patients who were on high doses of glucocorticoids to control primarily arthritic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/22\">",
"       22",
"      </a>",
"      ]. Three patients discontinued methotrexate because of side effects. In six of the remaining nine patients, the glucocorticoid dose was reduced by an average of 42 percent. In a prospective, double-blind trial, 41 patients were randomized to methotrexate plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or to prednisone alone [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/23\">",
"       23",
"      </a>",
"      ]. Compared with prednisone, methotrexate plus prednisone was more effective in controlling articular activity, while permitting a lower prednisone dose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    can be used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , especially in patients unable to tolerate or to take methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medications that have been used for lupus arthritis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/4\">",
"     4",
"    </a>",
"    ]. A low dose of a tricyclic antidepressant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    5 to 30 mgHS) is often useful when pain has been unresponsive to the above measures. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Fibromyalgia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Total joint arthroplasty is infrequently required in patients with SLE. In one cohort of 500 patients with SLE followed at a single center in Great Britain, arthritis was present in 94 percent, but only 4 percent (19 patients) underwent at least one total joint replacement between 1978 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/28\">",
"     28",
"    </a>",
"    ]. The findings most often associated with undergoing joint replacement were osteonecrosis and overlapping features of rheumatoid arthritis (RA) (in 10 and 11 patients, respectively).",
"   </p>",
"   <p>",
"    An analysis of data from a large hospitalization database in the United States suggested that patients with SLE are at increased risk for postoperative mortality after joint arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study, using data from joint arthroplasties in 5585; 53,442; and 1,481,321 patients with SLE, with RA, and in the general population, respectively, risks of post-arthroplasty mortality after hip replacement were significantly increased in patients with SLE compared with the general population and showed a trend toward an increase following knee surgery (odds ratios of 4.0, 95% CI 1.9-8.0, and of 1.2, 95% CI 0.2-7.5, respectively). There was no difference in mortality rates between patients with RA and the controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUBCUTANEOUS NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous nodules that occur characteristically in patients with RA have been noted in 5 to 7 percent of patients with SLE. Nodules are generally seen in association with active disease in patients with disease that resembles RA (eg, rheumatoid factor positivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. The pathology of these nodules is similar to that of rheumatoid nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OSTEONECROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis (also called avascular, aseptic, or ischemic necrosis) in patients with SLE is most common in the femoral head, although the humeral head, tibial plateau, and scaphoid navicular can also be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1,31-33\">",
"     1,31-33",
"    </a>",
"    ]. Osteonecrosis is usually bilateral and is often asymptomatic. When symptoms occur, femoral head involvement usually manifests as pain in the groin, especially with weightbearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteonecrosis has been reported in 2 to 30 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/34\">",
"     34",
"    </a>",
"    ]. This wide range reflects the use of different techniques in defining this disorder, from the less sensitive plain film radiography to the very sensitive MRI; variations in glucocorticoid dosing; and different periods of follow-up. As an example, one report followed 228 patients with SLE for a mean period of 31 months. Nine percent had osteonecrosis, and it was estimated that the frequency would rise to 30 percent at 10 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/35\">",
"     35",
"    </a>",
"    ]. However, among 744 patients with SLE followed a mean of eight years, 13 percent developed osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/36\">",
"     36",
"    </a>",
"    ]. Disease activity as measured by system lupus erythematosus disease activity index (SLEDAI) scoring is a major risk factor for the development of osteonecrosis in early SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early lesions are detectable by MRI, while plain radiography only detects late lesions. Most lesions on plain radiography develop four to seven years after the diagnosis of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/35\">",
"     35",
"    </a>",
"    ]. If one suspects osteonecrosis based upon clinical symptoms and if a hip radiograph is negative, a MRI may be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/34\">",
"     34",
"    </a>",
"    ]. We usually perform a MRI only in patients with suggestive symptoms (eg, hip or groin pain). If the MRI is negative, a bone scan may occasionally detect an early lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/34\">",
"     34",
"    </a>",
"    ]. If these tests are equivocal, the diagnosis may be established by an abnormal intraosseous phlebogram and by the demonstration of an elevated intramedullary pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanism and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis begins by interruption of blood supply to the bone. Subsequently, the adjacent area becomes hyperemic, resulting in demineralization, trabecular thinning, and, if stressed, collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with SLE who have taken glucocorticoids are at greatest risk, although occasional cases have been noted in the absence of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/33\">",
"     33",
"    </a>",
"    ]. Osteonecrosis often develops a relatively short time after the onset of glucocorticoid therapy, within a month in some patients who receive high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/32,39-42\">",
"     32,39-42",
"    </a>",
"    ]. One prospective study, for example, evaluated 60 patients with SLE over a period of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/43\">",
"     43",
"    </a>",
"    ]. In that study, patients who had no MRI abnormalities in the femoral head during the first year of follow-up were unlikely to develop osteonecrosis at a later date [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/43\">",
"     43",
"    </a>",
"    ]. Glucocorticoid dose and duration of therapy seem to be important factors in the development of osteonecrosis, although there is some controversy about this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/32,34,35,39-41,44,45\">",
"     32,34,35,39-41,44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors for osteonecrosis have also been suggested. The Raynaud phenomenon and hyperlipidemia were associated in one retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/46\">",
"     46",
"    </a>",
"    ] but not in a larger study of 744 patients followed for an average of 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/45\">",
"     45",
"    </a>",
"    ]. In the latter study, the presence of arthritis, use of glucocorticoids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytotoxic medication were associated with a significantly increased risk of osteonecrosis. Cytotoxic treatment was also identified in a prospective study of 571 patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/33\">",
"     33",
"    </a>",
"    ]. Antiphospholipid antibodies are not risk factors for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of osteonecrosis is problematic. The best initial approach is prevention by avoiding chronic therapy with high-dose glucocorticoids. Once the condition develops, it may only be recognized after bony collapse has occurred, and joint arthroplasty (replacement) may be necessary. Patients with SLE who require total hip replacements do as well as those with other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/48\">",
"     48",
"    </a>",
"    ]. The overall approach to therapy of osteonecrosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of trabecular bone density is a significant problem in patients with SLE. Trabecular bones (eg, ribs, vertebrae) are more likely to be involved than long cortical bones [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/49\">",
"     49",
"    </a>",
"    ]. There are no symptoms unless fractures occur.",
"   </p>",
"   <p>",
"    A study of 516 women with SLE seen between 1995 and 2000 found that 205 had a determination of bone mineral density (BMD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/50\">",
"     50",
"    </a>",
"    ]. Those who had a BMD measurement tended to have more traditional risk factors for osteoporosis (eg, age, postmenopausal status), to have higher lupus disease activity, to more frequently have renal involvement, to have evidence of increased end-organ damage, and to have higher use of glucocorticoids and other immunosuppressives. Among the women whose BMDs were measured, 18 percent had osteoporosis, and 49 percent had osteopenia. Low bone density was associated with increasing age and a higher amount of lupus-related end-organ damage but was not associated with disease activity or glucocorticoid use. The lack of an association with glucocorticoid use in this study was surprising and unexplained. However, the absence of an association with glucocorticoid use and a significant link to SLE-associated damage have been corroborated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors for osteoporosis include smoking, physical inactivity, chronic systemic inflammation, and premature gonadal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/53\">",
"     53",
"    </a>",
"    ]. Other noteworthy associations between SLE and bone health reported in one review included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoporosis of the lumbosacral (LS) spine was reported to be present in 3 to 24 percent of SLE patients and in the hip in 2 to 6 percent.",
"     </li>",
"     <li>",
"      Osteopenia is reported to be present in the LS spine in 35 to 62 percent of SLE patients and in the hip in 29 to 48 percent.",
"     </li>",
"     <li>",
"      SLE confers an approximately fivefold increased risk of fracture, occurring in 9 to 12 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of those who sustain fractures, 90 percent are at least osteopenic; 32 percent are osteoporotic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, prevention, recognition, and treatment of bone mineral loss are important for the prevention of fractures.",
"   </p>",
"   <p>",
"    Women with SLE generally avoid sun exposure and are, therefore, more dependent upon exogenous supplies of vitamin D.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 14 of 25 women with SLE had decreased serum levels of 25-hydroxyvitamin D (less than 50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/54\">",
"       54",
"      </a>",
"      ]. The mean serum concentration of calcitriol (1-25-dihydroxyvitamin D), the most active metabolite of vitamin D, was lower among those patients who were being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"       \"Metabolism of vitamin D\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another study of 92 patients with SLE, 69 (75 percent) had vitamin D insufficiency (&lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      25-hydroxyvitamin D levels), and 14 (15 percent) had vitamin D deficiency (&lt;10",
"      <span class=\"nowrap\">",
"       ng/ml)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/55\">",
"       55",
"      </a>",
"      ]. Lower levels of vitamin D were associated with a history of photosensitivity and use of sunscreen. In contrast to the lower levels of 1-25-dihydroxyvitamin D seen in association with use of hydroxychloroquine in an earlier study cited above [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/54\">",
"       54",
"      </a>",
"      ], high levels of 25-hydroxyvitamin D were predicted by the use of hydroxychloroquine and by the use of supplemental calcium with vitamin D.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of reduced serum calcitriol in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is uncertain, since there is some evidence that hydroxychloroquine may protect against osteoporosis. In a retrospective study of 90 glucocorticoid-treated women with SLE, the administration of hydroxychloroquine correlated with higher bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with SLE also may have low serum levels of 25-hydroxyvitamin D (calcidiol). This was illustrated in a case control study of 23 male SLE patients; 62 percent had hypovitaminosis D [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the prevalence of osteoporosis was no higher than in age-matched controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain general principles should be followed in all patients to minimize bone loss, particularly in patients receiving therapy with glucocorticoids. The prevention and treatment of glucocorticoid-induced osteoporosis is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, important elements in management include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modification of lifestyle factors (ie, elimination of cigarette smoking, limitation of alcohol consumption, and maintenance of a weight-bearing exercise regimen) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H2#H2\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'General measures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Limitation of glucocorticoid therapy to the lowest possible dose and duration required (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H2#H2\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'General measures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of calcium and vitamin D. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H3#H3\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Calcium and vitamin D'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of bone mineral density and administration of pharmacologic therapy. In most patients, the therapy of choice is a bisphosphonate. Other interventions may be appropriate in selected patients, such as hormone therapy and use of teriparatide (parathyroid hormone). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H622797#H622797\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Candidates for pharmacologic therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H2707796#H2707796\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Choice of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H2707788#H2707788\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Monitoring'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H21#H21\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Guidelines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither estrogens nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , a selective estrogen receptor modulator, should be used in women who have other risk factors of venous thromboembolic disease, particularly those with the antiphospholipid syndrome (APS). Raloxifene use is associated with an increased risk of venous thromboembolism that is similar to that seen with estrogen use. Whether or not raloxifene use affects the risk for atherosclerotic cardiovascular disease is unknown. Use of bisphosphonates rather than raloxifene is suggested for those with SLE and other risk factors for cardiovascular disease (eg, hypertension, hyperlipidemia, cigarette smoking, diabetes mellitus, etc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    in the prevention or treatment of osteoporosis in postmenopausal women with SLE was suggested by the results of a small study of 33 Chinese women who were randomly assigned to raloxifene (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to placebo; all patients received supplemental calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/58\">",
"     58",
"    </a>",
"    ]. None of the patients had a major flare during the study. Raloxifene use was associated with maintenance of bone mineral density, while those who received placebo and calcium had a significant decrease in bone mineral density.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FRACTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia and osteoporosis (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Osteoporosis'",
"    </a>",
"    above) may account for much of the increased risk of fracture seen in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The magnitude of the fracture risk is illustrated by a retrospective, cohort study of approximately 700 women with SLE and an equivalent number of age-matched controls; a fivefold increase in fracture among those with SLE was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/59\">",
"     59",
"    </a>",
"    ]. Variables that were significantly associated with the time from diagnosis to that of fracture included older age at the time of diagnosis of SLE, longer disease duration, longer duration of glucocorticoid use, less use of oral contraceptives, and menopause status.",
"   </p>",
"   <p>",
"    The presence of antiphospholipid antibodies (aPL) may be associated with an increased risk of nontraumatic fractures. This was illustrated in one study that linked aPL to an increased risk of metatarsal (stress) fractures in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/61\">",
"     61",
"    </a>",
"    ]. Vertebral fractures, found in up to 20 percent of patients with SLE, have been associated with intravenous use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at any time and with male sex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MUSCLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myalgias, muscle tenderness, or muscle weakness occurs in up to 70 percent of patients with SLE and may be the reason that the patient initially seeks medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1,63-65\">",
"     1,63-65",
"    </a>",
"    ]. However, severe muscle weakness, atrophy, or myositis is relatively uncommon (7 to 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/1,66\">",
"     1,66",
"    </a>",
"    ]. Pathologic examination reveals perivascular and perifascicular mononuclear cell infiltrates in 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/12\">",
"     12",
"    </a>",
"    ]. Other histologic findings include muscle atrophy, microtubular inclusions, mononuclear infiltrate, fiber necrosis, and, occasionally, vacuolated muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to SLE itself, glucocorticoids and antimalarial drugs can cause muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Medication-induced myopathy is generally easily differentiated from SLE-induced myopathy or myositis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum levels of creatine kinase (CK)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aldolase are usually normal in patients with glucocorticoid-induced myopathy, although lactate dehydrogenase (LDH) values may be elevated in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/68\">",
"       68",
"      </a>",
"      ]. Muscle biopsy reveals an increase in the number of sarcolemmal nuclei, rowing and centralization of the nuclei, vacuolization and loss of fiber cross-striations, and phagocytosis but does not reveal the inflammation characteristic of SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscle enzymes are also typically normal in patients with antimalarial-induced myopathy. Muscle biopsy may reveal vacuolar changes but not inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Establishing the correct diagnosis has important implications for therapy. Lupus myositis responds to treatment with glucocorticoids (using a regimen similar to that in polymyositis), while glucocorticoid-induced myopathy responds to a reduction in or withdrawal of glucocorticoid therapy. Antimalarial myopathy responds to stopping the drug, but it may take months for the myopathy to improve, partly due to the long half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (months). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medications that may also cause myopathy, most often resulting in myalgias but also to more severe muscle disease, include statins being used for treatment of hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FIBROMYALGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 61 percent of patients have been noted to have fibromyalgia-like symptoms and tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/70\">",
"     70",
"    </a>",
"    ], although other studies suggest a frequency of 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23753/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The symptoms are detrimental to the patient&rsquo;s quality of life and may increase disability. It is important to remember that treatment with glucocorticoids can cause myalgia, as can glucocorticoid withdrawal, and that symptoms and tenderness suggestive of fibromyalgia in patients with SLE usually do not represent active lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499515\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthritis and arthralgias have been noted in up to 95 percent of patients with systemic lupus erythematosus (SLE) and can precede the diagnosis of SLE by months or years. The arthritis tends to be migratory, compared with rheumatoid arthritis (RA), and plain radiographic evidence of erosions is rare. Morning stiffness is usually brief, and pain may exceed objective physical findings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Arthritis and arthralgias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthritis in patients with SLE usually responds to nonsteroidal antiinflammatory drugs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      . Patients with arthralgia may benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . Glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and other immunosuppressives may be required in some patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Joint effusions are infrequent in patients with SLE and are usually small, with clear or slightly cloudy, mildly inflammatory fluid, if present. Synovial histopathology exhibits nonspecific changes. (See",
"      <a class=\"local\" href=\"#H370426595\">",
"       'Synovial involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small nodules resembling rheumatoid nodules may be seen in a small number of patients, usually in association with active disease in patients with disease that resembles RA. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Subcutaneous nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteonecrosis has been reported in 2 to 30 percent of patients with SLE; it is most common in the femoral head, although the humeral head, tibial plateau, and scaphoid navicular can also be affected. This wide range reflects the use of different techniques to detect the disorder and different periods of follow-up. Patients with SLE who have taken glucocorticoids are at greatest risk, although it occasionally occurs in patients with SLE in the absence of such therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Osteonecrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoporosis, characterized by loss of trabecular bone mass, is a significant problem in patients with SLE. Trabecular bones (eg, ribs, vertebrae) are more likely to be involved than long cortical bones. Risk is multifactorial and is associated with increasing age and a higher amount of lupus related end-organ damage. However, it is not associated with disease activity or glucocorticoid use. Prevention, recognition, and treatment of bone mineral loss are important for the prevention of fractures. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention and treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myalgias, muscle tenderness, or muscle weakness occurs in up to 70 percent of patients with SLE. However, severe muscle weakness, atrophy, or myositis is relatively uncommon (7 to 15 percent). In addition to SLE itself, glucocorticoids and antimalarial drugs can cause muscle weakness. Lupus myositis responds to treatment with glucocorticoids (using a regimen similar to that in polymyositis), while glucocorticoid-induced myopathy responds to a reduction in or withdrawal of glucocorticoids. Antimalarial myopathy responds to stopping the drug, but it may take months for the myopathy to improve. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Muscle disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibromyalgia is common in patients with SLE, can adversely affect quality of life, and may increase disability. Withdrawal of glucocorticoid therapy can cause myalgia, and symptoms and tenderness suggestive of fibromyalgia in patients with SLE should be distinguished from active lupus. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Fibromyalgia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dubois EL, Wallace DJ. Clinical and laboratory manifestations of SLE, Dubois LE, Wallace DJ, Dubois EL (Eds), Lea and Febiger, Philadelphia 1987. p.317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/2\">",
"      Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/3\">",
"      van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998; 57:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/4\">",
"      Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol 2009; 23:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/5\">",
"      Franceschini F, Cretti L, Quinzanini M, et al. Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La. Lupus 1994; 3:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/6\">",
"      Ostendorf B, Scherer A, Specker C, et al. Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum 2003; 48:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/7\">",
"      Weissman BN, Rappoport AS, Sosman JL, Schur PH. Radiographic findings in the hands in patients with systemic lupus erythematosus. Radiology 1978; 126:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/8\">",
"      Ossandon A, Iagnocco A, Alessandri C, et al. Ultrasonographic depiction of knee joint alterations in systemic lupus erythematosus. Clin Exp Rheumatol 2009; 27:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/9\">",
"      Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/10\">",
"      Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009; 36:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/11\">",
"      Santiago MB, Galv&atilde;o V. Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine (Baltimore) 2008; 87:37.",
"     </a>",
"    </li>",
"    <li>",
"     Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.",
"    </li>",
"    <li>",
"     Buyon JP, Zuckerman JD. Articular manifestations of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Lahita RG (Ed), John Wiley and Sons, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/14\">",
"      Morgan J, McCarty DJ. Tendon ruptures in patients with systemic lupus erythematosus treated with corticosteroids. Arthritis Rheum 1974; 17:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/15\">",
"      Pekin TJ Jr. Zvaifler NJ: Synovial fluid findings in systemic lupus erythematosus (SLE). Arthritis Rheum 1970; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/16\">",
"      Labowitz R, Schumacher HR Jr. Articular manifestations of systemic lupus erythematosus. Ann Intern Med 1971; 74:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/17\">",
"      Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/18\">",
"      Schenfeld L, Gray RG, Poppo MJ, et al. Bacterial monarthritis due to Neisseria meningitidis in systemic lupus erythematosus. J Rheumatol 1981; 8:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/19\">",
"      Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/20\">",
"      Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/21\">",
"      A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/22\">",
"      Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/23\">",
"      Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/24\">",
"      Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998; 25:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/25\">",
"      Wong JM, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 2005; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/26\">",
"      Tam LS, Li EK, Wong CK, et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 2006; 65:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/27\">",
"      Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/28\">",
"      Mour&atilde;o AF, Amaral M, Caetano-Lopes J, Isenberg D. An analysis of joint replacement in patients with systemic lupus erythematosus. Lupus 2009; 18:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/29\">",
"      Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol 2010; 37:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/30\">",
"      Hahn BH, Yardley JH, Stevens MB. \"Rheumatoid\" nodules in systemic lupus erythematosus. Ann Intern Med 1970; 72:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/31\">",
"      Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1986; 29:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/32\">",
"      Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978; 138:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/33\">",
"      Calvo-Al&eacute;n J, McGwin G, Toloza S, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 2006; 65:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/34\">",
"      Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 2003; 25:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/35\">",
"      Dimant J, Ginzler EM, Diamond HS, et al. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 1978; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/36\">",
"      Gladman DD, Chaudhry-Ahluwalia V, Iba&ntilde;ez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/37\">",
"      Fialho SC, Bonf&aacute; E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 2007; 16:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/38\">",
"      Zizic TM, Hungerford DS, Stevens MB. Ischemic bone necrosis in systemic lupus erythematosus. II. The early diagnosis of ischemic necrosis of bone. Medicine (Baltimore) 1980; 59:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/39\">",
"      Nagasawa K, Tsukamoto H, Tada Y, et al. Imaging study on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long-term observations. Br J Rheumatol 1994; 33:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/40\">",
"      Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol 1989; 16:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/41\">",
"      Massardo L, Jacobelli S, Leissner M, et al. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1992; 1:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/42\">",
"      Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/43\">",
"      Sugano N, Ohzono K, Masuhara K, et al. Prognostication of osteonecrosis of the femoral head in patients with systemic lupus erythematosus by magnetic resonance imaging. Clin Orthop Relat Res 1994; :190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/44\">",
"      Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; 1:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/45\">",
"      Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, et al. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 2001; 28:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/46\">",
"      Cozen L, Wallace DJ. Risk factors for avascular necrosis in systemic lupus erythematosus. J Rheumatol 1998; 25:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/47\">",
"      Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000; 59:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/48\">",
"      Zangger P, Gladman DD, Urowitz MB, Bogoch ER. Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus. J Rheumatol 2000; 27:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/49\">",
"      Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 1993; 36:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/50\">",
"      Pineau CA, Urowitz MB, Fortin PJ, et al. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 2004; 13:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/51\">",
"      Lee C, Almagor O, Dunlop DD, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 2006; 45:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/52\">",
"      Almehed K, Forsblad d'Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford) 2007; 46:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/53\">",
"      Panopalis P, Yazdany J. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/54\">",
"      Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001; 28:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/55\">",
"      Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008; 47:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/56\">",
"      Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001; 28:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/57\">",
"      Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/58\">",
"      Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005; 52:3997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/59\">",
"      Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/60\">",
"      Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 2007; 34:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/61\">",
"      Sangle S, D'Cruz DP, Khamashta MA, Hughes GR. Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis 2004; 63:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/62\">",
"      Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:2044.",
"     </a>",
"    </li>",
"    <li>",
"     Stevens MB. Musculoskeletal Manifestations. In: The Clinical Management of Systemic Lupus Erythematosus, Schur, PH (Eds), Grune and Stratton, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/64\">",
"      Isenber DA, Snaith ML. Muscle Disease in systemic lupus erythematosus: a study of its nature, frequency and cause. J Rheumatol 1981; 8:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/65\">",
"      Greco CM, Rudy TE, Manzi S. Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory. Pain Med 2003; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     Ropes MW. Systemic lupus erythematosus, Harvard University Press, Cambridge 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/67\">",
"      Finol HJ, Montagnani S, M&aacute;rquez A, et al. Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus. J Rheumatol 1990; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/68\">",
"      Kanayama Y, Shiota K, Horiguchi T, et al. Correlation between steroid myopathy and serum lactic dehydrogenase in systemic lupus erythematosus. Arch Intern Med 1981; 141:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/69\">",
"      Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968; 123:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/70\">",
"      Buskila D, Press J, Abu-Shakra M. Fibromyalgia in systemic lupus erythematosus: prevalence and clinical implications. Clin Rev Allergy Immunol 2003; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/71\">",
"      Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23753/abstract/72\">",
"      Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4673 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23753=[""].join("\n");
var outline_f23_12_23753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H499515\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTHRITIS AND ARTHRALGIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H370426595\">",
"      Synovial involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUBCUTANEOUS NODULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OSTEONECROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanism and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MUSCLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FIBROMYALGIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H499515\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/47/24316\" title=\"table 1\">",
"      Lupus arthritis versus RA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1030?source=related_link\">",
"      Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23754="Treatment of the antiphospholipid syndrome";
var content_f23_12_23754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the antiphospholipid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23754/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/12/23754/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/12/23754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid antibody syndrome (APS) is defined by two major components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence in the serum of at least one type of autoantibody known as an antiphospholipid antibody (aPL). aPL are directed against phospholipid-binding plasma proteins.",
"     </li>",
"     <li>",
"      The occurrence of at least one clinical feature from a diverse list of potential disease manifestations, the most common of which are categorized as venous or arterial thromboses,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pregnancy morbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most of the clinical manifestations of APS can occur in other disease populations, in the APS, they occur by definition in the context of aPL. aPL are directed against serum proteins bound to anionic phospholipids and may be detected as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lupus anticoagulants",
"     </li>",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Antibodies to &szlig;2 glycoprotein-I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    APS occurs either as a primary condition or in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    The treatment of the APS will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of APS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review begins with a discussion of the current APS treatment modalities and then considers specific clinical settings in which treatment must be addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CURRENT THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy for the APS is largely the same regardless of whether the disorder is classified as primary APS or as secondary to SLE. Current therapies for the APS include the following medications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"     </li>",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with SLE are also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , which may have some benefit for patients at risk of APS.",
"   </p>",
"   <p>",
"    Treatment approaches to the catastrophic APS and investigational therapies are discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Catastrophic APS'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H35\">",
"     'Investigational treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many APS-related events can be managed on an outpatient basis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The following four criteria can help to identify patients with deep venous thrombosis (DVT) for whom outpatient treatment might",
"    <strong>",
"     not",
"    </strong>",
"    be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Massive DVT",
"     </li>",
"     <li>",
"      Symptomatic pulmonary embolism",
"     </li>",
"     <li>",
"      High risk of bleeding with anticoagulant therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"       \"Therapeutic use of warfarin\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Presence of comorbid conditions or other factors that warrant hospital care",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30829462\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to thrombosis in the APS is identical to that of many other thromboses. For acute thrombotic events in patients with APS, the first therapy is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Low molecular weight (LMW) heparin has replaced unfractionated heparin as the standard of care for most thrombotic events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Warfarin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is usually given simultaneously with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and is overlapped with warfarin for a minimum of four to five days until the International Normalized Ratio (INR) has been within the therapeutic range (2.0 to 3.0) for two consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several LMW products are now available for clinical use. Dosing requirements are individualized for each product [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/10\">",
"     10",
"    </a>",
"    ]. The advantages of LMW heparins over unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    also plays a critical role in the treatment of the pregnant patient with the APS because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is contraindicated in early pregnancy. Treatment of the pregnant APS patient is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\", section on 'Heparin/heparin with aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is preferred to LMW heparin in certain circumstances. The major potential advantage of unfractionated heparin over LMW heparin is in the setting of hemorrhage (a rare complication of the APS). Unfractionated heparin can be reversed quickly with protamine, while LMW is not completely reversible with this approach. The major setting in which hemorrhage is due to APS is when antibodies to prothrombin are present. Heparin monitoring, including monitoring in the setting of a prolonged baseline activated partial thromboplastin time, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Bleeding episodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H10#H10\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Prolonged baseline aPTT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following stabilization of the patient,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is begun. Warfarin is the standard of care for the chronic management of patients with APS who are not pregnant. The International Normalized Ratio (INR) should be maintained between 2.0 and 3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, aPL may create problems in monitoring of the INR. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Intensity of anticoagulation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Problems in monitoring INR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two antiplatelet agents that have been evaluated in patients with APS are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In retrospective series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has been of minimal or no benefit for the prevention of thrombotic APS manifestations in patients who have experienced previous events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Some, but not all, studies suggest that aspirin (81",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    reduces the risk of thrombosis in aPL positive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/16\">",
"     16",
"    </a>",
"    ]. The decision to recommend low dose aspirin to a patient should be based upon cardiovascular disease risk prediction tools and prevention guidelines. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not advise the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for the treatment of APS. It has been proposed as a potentially useful agent for this condition, but there are no studies or data from randomized trials that have evaluated its efficacy and safety for patients with APS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) is useful for the prevention of thrombosis in patients with APS or patients with aPL who have not had a clinical event [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. There are no randomized trials that have evaluated this possibility. It has been hypothesized that HCQ may benefit patients with aPL and a high risk of vascular events through antiplatelet effects and by reducing homocysteine levels, lupus disease activity and aPL titers, and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/23\">",
"     23",
"    </a>",
"    ]. The range of evidence includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from animal models and limited indirect evidence from studies in humans suggesting that HCQ may be useful in APS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HCQ reduces the size and persistence of venous thrombi in a rodent model of the APS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In vitro data from a human study suggests that HCQ reverses platelet activation induced by IgG aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Representative evidence from the retrospective studies that have suggested an association of HCQ use with reduced risk of thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a cross-sectional study designed to analyze risk factors for the APS, 77 APS patients with thrombotic events and 56 asymptomatic aPL-positive patients were evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/18\">",
"       18",
"      </a>",
"      ]. The findings suggested that the probability of thrombosis was statistically significantly decreased by use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HCQ in asymptomatic patients with positive aPL testing. All patients in the study who received HCQ had a systemic rheumatic disease, such as SLE.",
"     </li>",
"     <li>",
"      In another study, which involved 288 patients with SLE, half of whom were positive for aPL, a greater duration of HCQ use was associated with a reduced risk of thromboembolic events in both patients with and without aPL, but it was not statistically significant in the aPL-positive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies that have investigated whether low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    can prevent thromboembolic events in patients with aPL were performed in patients with SLE. In those patients, some studies have suggested that HCQ may prevent such thromboembolic events while other studies could not confirm this observation. Furthermore, it is not clear whether HCQ may have this possible benefit through its effect on SLE itself rather than through aPL mediated thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treating APS varies with the clinical presentation. Our approach is supported by a systematic review and the conclusions of a multispecialty task force of experts in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the rate of recurrent thromboembolism after an initial event in patients with APS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/14,15,27\">",
"     14,15,27",
"    </a>",
"    ]. Considering all patients, regardless of the presence or absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, recurrent events were seen in up to 11 percent of patients per year; some patients had multiple recurrences. In two studies, the rates of recurrence among untreated patients were 29 and 19 percent per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The frequency of recurrent clinical events in patients with the APS and the potentially devastating nature of these events are strong arguments for lifelong anticoagulation in most patients. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Duration of warfarin use'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues regarding the role of prophylaxis for patients with aPL in the absence of clinical events have long been debated. Retrospective and prospective observational studies and controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of thrombotic events in people with aPL who have no history of arterial or venous thromboembolism have had disparate results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/19,28-30\">",
"     19,28-30",
"    </a>",
"    ]. The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study consisted of two separate investigations involving patients who were asymptomatic but persistently aPL-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter trial randomly assigned asymptomatic individuals who were persistently aPL-positive to receive placebo or 81",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Forty-eight patients were randomized to aspirin, and 50 to placebo. Mean follow-up was 2.3 years.",
"     </li>",
"     <li>",
"      A separate observational study done in parallel involved asymptomatic, persistently aPL-positive patients who were taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      already or declined randomization. In this nonrandomized investigation, 61 individuals received aspirin and 13 did not. The patients were followed for a mean of 2.46 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients in both of these investigations had an underlying systemic autoimmune disease, most commonly SLE.",
"   </p>",
"   <p>",
"    The results of the APLASA trial and study were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial, there was no statistically significant difference between the two treatment groups in the incidence of acute thrombosis. The rate among individuals in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      group was 2.75 per 100 patient-years, compared with 0 per 100 patient-years among individuals in the placebo group.",
"     </li>",
"     <li>",
"      In the observational study, the incidence of acute thrombosis was 2.70 per 100-patient years among individuals who took",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , compared with 0 per 100 patient years among those who did not.",
"     </li>",
"     <li>",
"      Among the 13 thrombotic events observed in the combined randomized trial and observational APLASA study data, only one occurred in a patient who did not have additional risk factors for thrombosis (eg, hypertension, smoking, obesity, estrogen replacement therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conclusions of the APLASA trial were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic individuals who are persistently positive for aPL have a low annual incidence of acute thrombosis.",
"     </li>",
"     <li>",
"      These individuals do not benefit from low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Thrombotic events in this population are unlikely in the absence of additional risk factors for thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A special task force at the 13",
"    <sup>",
"     th",
"    </sup>",
"    International Congress on Antiphospholipid Antibodies presented the following recommendations based upon the evidence available in 2011 for asymptomatic aPL carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strict control of cardiovascular risk factors should be accomplished in all individuals with a high risk aPL profile.",
"     </li>",
"     <li>",
"      Individuals with aPL should receive thromboprophylaxis with usual doses of low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in high risk situations, such as surgery, prolonged immobilization and the puerperium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     SLE with aPL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE and aPL have an increased risk of thromboembolic disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent pregnancy loss; prophylactic treatment may decrease such risk. In two series of patients with SLE and aPL, approximately 20 to 50 percent of patients met criteria for APS at 10- to 20-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/19,31,32\">",
"     19,31,32",
"    </a>",
"    ]. Among patients with anticardiolipin antibodies, the higher the titer, the greater is the risk of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use the following approach in asymptomatic patients with SLE who have aPL (but without a diagnosis of APS), with recognition that data supporting benefit are limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of any contraindication to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , prophylactic therapy with a low-dose (81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      of aspirin is advised for patients with SLE or another underlying connective tissue disorder, if other risk factors for thromboembolic disease, such as cardiovascular or genetic risk factors, are present [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/33-35\">",
"       33-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with aPL should avoid oral contraceptives, particularly those with high estrogen content.",
"     </li>",
"     <li>",
"      Modifiable risk factors that predispose to thrombosis (eg, venous stasis, hypertension, hyperlipidemia, cigarette smoking) should be addressed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We are also in agreement with the recommendations from a special task force at the 13",
"    <sup>",
"     th",
"    </sup>",
"    International Congress on Antiphospholipid Antibodies for SLE patients with aPL, which include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular assessment of patients with SLE for the presence of aPL. However, the task force did not define &ldquo;regular assessment.&rdquo; We obtain testing for the presence of IgG and IgM anticardiolipin and anti-&beta;2-glycoprotein I antibodies and lupus anticoagulant during the initial diagnostic evaluation or at the time of diagnosis of SLE if not previously obtained. We repeat such testing during follow-up in patients in whom there is a clinical suspicion of APS.",
"     </li>",
"     <li>",
"      In patients with SLE and a positive LA or isolated persistent aCL at medium-high titers, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ) and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      as primary thromboprophylaxis. The use of hydroxychloroquine is supported by several studies and systematic reviews [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]; however, there are no randomized trials of the combination of HCQ and aspirin in comparison with placebo or either alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential benefit of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    prophylaxis was illustrated in an observational study that followed 144 patients with SLE who were aPL-positive for a median of 104 months and compared them with a group of 144 patients with SLE who were aPL-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/19\">",
"     19",
"    </a>",
"    ]. Seventeen of the aPL patients were LAC-positive, and 115 had IgG aCL antibodies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombotic events developed in 29 of those who were APL-positive versus 11 in those who were aPL-negative.",
"     </li>",
"     <li>",
"      Those with thromboses were more likely to have repeatedly positive IgG (79 percent) than those without thromboses (37 percent).",
"     </li>",
"     <li>",
"      Eighty-seven of the aPL-positive patients took low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ; those with APL who took aspirin, and those who took it longer, were less likely to have a thrombotic event.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      use was associated with a statistically significant reduced risk of thrombotic events in aPL-negative patients and showed a trend that did not achieve statistical significance towards protection in aPL-positive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that in these longer studies (as compared with the APLASA study), low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    does tend to significantly reduce the risk of thromboses in aPL-positive SLE patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) in patients with APS is the same as that for idiopathic thromboembolic disease. The standard of care for both of these clinical complications is treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The general treatment approaches to these disease complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intensity of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial debate has surrounded the intensity and duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy in patients with APS. The current standard of care for the long-term management of the APS is to maintain the INR between 2.0 and 3.0 for an initial venous thromboembolic event [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. Observational studies in the 1990s suggested that optimal anticoagulation regimens were those that maintained the INR between 3.0 and 4.0, and some controversy remains [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. However, high-intensity therapy is associated with no demonstrable additional benefit and may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The current standard of care for the long-term management of the APS is to maintain the INR between 2.0 and 3.0.",
"   </p>",
"   <p>",
"    The following randomized trials provided the evidence supporting the present standard [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    In one trial, 114 patients with aPL and previous thrombosis were randomly assigned to receive either moderate- or high-intensity treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . For the moderate-intensity treatment group, the target INR was 2.0 to 3.0; for the high-intensity group, the target INR was 3.1 to 4.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11\">",
"     11",
"    </a>",
"    ]. The average attained INR was 2.3 and 3.3 in the two groups.",
"   </p>",
"   <p>",
"    The following findings were noted at a mean follow-up of 2.7 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall rate of recurrent thromboembolic events was 7 percent.",
"     </li>",
"     <li>",
"      The rate was numerically but not statistically greater in the high-intensity group (10.7 versus 3.4 percent, hazard ratio 3.1, 95% CI 0.6-15.0).",
"     </li>",
"     <li>",
"      One-half of the recurrent thrombotic events in both groups occurred when the INR was less than 2.0.",
"     </li>",
"     <li>",
"      Major bleeding episodes occurred at similar rates in both groups (2.2 and 3.6 percent per year for the moderate- and high-intensity treatment groups, respectively.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the second trial, 109 APS patients with previous thromboses were randomly assigned to either standard or high-intensity",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (target INR 2.0 to 3.0 or 3.0 to 4.5, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean attained INR was 2.5 and 3.2 in the two groups.",
"   </p>",
"   <p>",
"    The following major findings were noted at a mean follow-up of 3.6 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent thrombosis occurred in 6 of 54 patients and 3 of 55 patients receiving high-intensity and moderate-intensity",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , respectively (11 versus 5.5 percent). This difference was not statistically significant (hazard ratio 1.97; 95% CI 0.49-7.89).",
"     </li>",
"     <li>",
"      Major bleeding episodes occurred in two and three patients in each group, but there was a significant increase in minor bleeding episodes with high-intensity therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2172855\">",
"    <span class=\"h3\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is disagreement among experts regarding the optimal therapy of APS with arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26,37\">",
"     26,37",
"    </a>",
"    ]. Some of us (authors Schur and Kaplan) treat such patients with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , with a target INR of 2.0 to 3.0, and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Other experts (including author Bermas) treat to a target INR of greater than 3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26,37\">",
"     26,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Duration of warfarin use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of anticoagulation for venous thromboembolic disease following a first event is uncertain in patients with APS. We recommend indefinite antithrombotic therapy in patients with definite APS and thrombosis. In patients with a first venous event, a known transient precipitating factor, and a nondiagnostic or low-risk aPL profile (an isolated, intermittently positive, low to medium titer anticardiolipin or anti-&beta;",
"    <sub>",
"     2",
"    </sub>",
"    GPI antibody), we suggest treating for a more defined period, such as three to six months. This approach is consistent with the systematic review and recommendations of the expert task force [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifelong therapy is prudent for most patients with APS. In a prospective study of 412 patients with a first episode of venous thromboembolism, the presence of anticardiolipin antibodies at the end of six months of treatment was associated with a doubling of the risk of recurrent thrombosis (29 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors of a 2006 systematic review concluded that anticoagulation is warranted for an indefinite period for patients with APS and venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/39\">",
"     39",
"    </a>",
"    ]. Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is warranted if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy must be discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If thrombotic events recur during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy despite INR levels that are within the target range of 2.0 to 3.0, the treatment alternatives include increasing the target INR (3.1 to 4.0) or adding low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , LMWH, or HCQ [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"     26",
"    </a>",
"    ]. The choice between these options is based in part upon patient characteristics (eg, reliability to maintain a higher INR, concern about bleeding), since there is a paucity of data on comparative efficacy. We prefer low-dose aspirin in view of the possible harm described in the randomized trials of higher intensity warfarin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A 2007 systematic review concluded that there was no role for the addition of low-dose ASA to warfarin therapy in patients with recurrent events and INR &gt;3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Warfarin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Low molecular weight heparin'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Aspirin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Hydroxychloroquine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Central nervous system manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major central nervous system manifestations of the APS are stroke and white matter lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued in 2006 by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association include the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For cases of cryptogenic ischemic stroke or transient ischemic attack (TIA) associated with aPL, antiplatelet therapy is reasonable. A 2007 systematic review of thrombotic disorders associated with aPL also suggested antiplatelet secondary prophylaxis for those with a stroke and a single positive, rather than repeatedly positive, test for aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with ischemic stroke or TIA who meet the criteria for the APS, we employ",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy with a target INR of 2.0 to 3.0. An alternative approach recommended by some experts is to target a higher INR of 3.0 to 4.0 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, cryptogenic stroke or TIA in patients with aPL satisfies the diagnostic criteria for APS. Thus, in the setting of a confirmed and otherwise unexplained thrombotic event associated with aPL, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy even in the absence of other APS manifestations.",
"   </p>",
"   <p>",
"    For those patients with aPL and at high risk for strokes, such as those with SLE, hypertension, diabetes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperlipidemia, we recommend ASA 81",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients without SLE, who experience a first non-cardioembolic cerebral arterial event in the setting of a low-risk aPL profile and reversible trigger factors, treatment with antiplatelet agents should be individualized based upon an estimate of the risk of recurrence and the severity of the event.",
"   </p>",
"   <p>",
"    For those with recurrent strokes despite \"adequate\" anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the options include a higher INR, adding ASA 81 mg, or switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other neuropsychiatric manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system involvement in APS may be associated with high-intensity lesions on magnetic resonance imaging studies (MRI) that are suggestive of a vasculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Neurologic syndromes besides stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with aPL in whom there is no clinical suspicion of an ischemic or embolic stroke but who have white matter lesions on MRI that are consistent with the APS, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is a reasonable initial approach.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    therapy may be appropriate in patients who, while on aspirin, develop documented cognitive deficits or clear progression of the white matter lesions on serial MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data regarding the efficacy of anticoagulation for other aPL-related neuropsychiatric symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiac manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major cardiac issues ensue from the APS: complications of cardiac valvulopathy and myocardial infarction from coronary artery thrombosis. Cardiac valvulopathy due to nonbacterial thrombotic endocardial deposits can cause systemic embolic complications. Antiplatelet therapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    do not necessarily cause regression of the valvular lesions, but may prevent clinical events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations for different types of cardiac involvement were made in a consensus report [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is suggested in patients with echocardiographic evidence of valvular thickening without clinical features of systemic embolization.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation (target INR 2.0 to 3.0) is suggested in patients with echocardiographic evidence of vegetations, clinical evidence of systemic embolization, or aPL-associated myocardial infarction.",
"      <br/>",
"      <br/>",
"      Recommendations of the American College of Chest Physicians (ACCP) for the treatment of nonbacterial thrombotic endocarditis (NBTE) differ from this approach; the ACCP suggests that patients with NBTE and systemic or pulmonary emboli should be treated with full-dose intravenous unfractionated heparin or subcutaneous low molecular weight heparin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/44\">",
"       44",
"      </a>",
"      ]. Warfarin was not suggested. It is unclear whether these recommendations can be generalized to patients with APS, who were not included in the cited studies supporting these recommendations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the renal complications that can occur in the APS are acute renal failure, frequent thromboses of arteriovenous grafts in patients on hemodialysis, and intrarenal and systemic clotting events in patients with a renal transplant. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=see_link\">",
"     \"Antiphospholipid syndrome and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hematologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic manifestations of the APS include thrombocytopenia and thrombotic thrombocytopenic",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome",
"    <span class=\"nowrap\">",
"     (TTP/HUS).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    mechanism of thrombocytopenia in the APS is believed to be the binding of aPL to platelet-associated phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with aPL and mild thrombocytopenia generally require no therapy for the thrombocytopenia itself. However, these patients may be hypercoagulable even in the setting of severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data suggesting that anticoagulation is an effective therapy for APS-associated thrombocytopenia. Although the optimal approach to patients with marked APS-associated thrombocytopenia remains uncertain, it is reasonable to treat such patients in a manner similar to those with chronic immune thrombocytopenia (ITP) (eg, with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , intravenous immune globulin, and other agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal success in the treatment of APS-related thrombocytopenia has been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/48\">",
"     48",
"    </a>",
"    ], low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/49\">",
"     49",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/50\">",
"     50",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with thrombocytopenia who develop a thromboembolic event, we suggest LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (goal INR 2.0 to 3.0) as in other patients with APS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     TTP/HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data related to the treatment of APS- or SLE-associated",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    are few. The standard of care for both idiopathic",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    occurring in the setting of SLE is to employ plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Catastrophic APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small subset of patients with APS has widespread thrombotic disease with visceral damage, referred to as the \"catastrophic\" APS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/52\">",
"     52",
"    </a>",
"    ]. Preliminary classification criteria for this disorder have been proposed (",
"    <a class=\"graphic graphic_table graphicRef62724 \" href=\"UTD.htm?35/51/36667\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prognosis for such patients without treatment is poor. The prognosis may be better with intensive treatment. The combination of anticoagulation, glucocorticoids, and plasma exchange with or without intravenous immune globulin has been associated with recovery rates ranging from 50 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A majority of patients with catastrophic APS who survive their initial illness remain free of further thromboembolic events when treated long-term with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . This was illustrated in an observational study of 58 survivors followed for an average of 67 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/56\">",
"     56",
"    </a>",
"    ]. Two-thirds had no recurrent clotting or emboli. Approximately 20 percent had recurrent APS-related events, but none had another episode of multiorgan failure. Among the recurrent thromboembolic events, 40 percent occurred in a perioperative period. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Perioperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recommended management for patients with the catastrophic APS (CAPS) consists of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/52,54,57\">",
"     52,54,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of any identifiable disorder that may have precipitated the catastrophic APS (eg, infection)",
"     </li>",
"     <li>",
"      Anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in the acute setting, followed by long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"     </li>",
"     <li>",
"      High-dose glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1 g intravenously daily for three days) followed by oral or parenteral therapy with the equivalent of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day",
"     </li>",
"     <li>",
"      If there are features of microangiopathy (eg, thrombocytopenia, microangiopathic hemolytic anemia), plasma exchange (see below) with or without IVIG (eg, 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for five days) are added to the above regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients resistant to standard therapies, several case reports have indicated that other approaches may be beneficial. In a patient with recurrent CAPS, despite maximal anticoagulation, immunosuppression, and plasma exchange, dramatic benefit was shown in a patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , a monoclonal antibody against the C5 component of complement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/58\">",
"     58",
"    </a>",
"    ]. In another case,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , the B cell-depleting anti-CD20 monoclonal antibody, was successfully employed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Therapeutic plasma exchange (TPE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that the half-lives of IgG and IgM antibodies are 22 and 5 days, respectively, and given that the anticardiolipin antibodies may be prime mediators in the thrombosis associated with CAPS, TPE, with its ability to rapidly remove these antibodies, becomes an appealing therapeutic option.",
"   </p>",
"   <p>",
"    Although plasma exchange for CAPS has never been investigated in a prospective, randomized study, a review of the first 250 patients entered into the CAPS Registry noted that the combination of TPE, anticoagulants, and steroids resulted in an overall 78 percent survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/54\">",
"     54",
"    </a>",
"    ], leading the authors to conclude that this treatment combination should be the first line of therapy for patients with CAPS. Given that the available data suggests substantial improvement in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], TPE can be considered in any patient presenting with CAPS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the optimum number of plasma exchange treatments has not been determined, one of the authors (Kaplan) has documented a predictable 95 percent lowering of both IgG and IgM anticardiolipin antibody after five consecutive plasma exchange treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with the APS are at increased risk for recurrent fetal loss, especially after 10 weeks of gestation. A detailed discussion of the treatment of pregnant women with the APS is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=see_link\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Perioperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for perioperative management of patients with APS are based upon anecdotal experience. The following approach has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is used preoperatively, it must be stopped a few days prior to surgery. The effects of warfarin may need to be reversed in patients requiring urgent surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Perioperative interruption and resumption of anticoagulation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Reversing the vitamin K antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For general surgery prophylaxis, 5000 units of unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or 30 to 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      are given subcutaneously one or two hours preoperatively.",
"     </li>",
"     <li>",
"      For orthopedic surgery, LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is preferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there are no immediate postoperative bleeding complications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be resumed the evening after surgery. Prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is continued until the INR is in therapeutic range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MONITORING ANTICOAGULATION WITH WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation may be associated with a number of challenges in monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Problems in monitoring INR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with the APS have marked fluctuations in the INR that make monitoring of the degree of anticoagulation difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/62\">",
"     62",
"    </a>",
"    ]. Factors that can affect the INR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Time of day &mdash; Some of the variation may relate to testing at different times of day following the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . Whenever it is practical to do so, patients should have their blood drawn at the same time of day and in the same laboratory.",
"     </li>",
"     <li>",
"      Drug interactions &mdash; Some fluctuations of the INR are due to the concurrent use of medications that affect",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      metabolism. Such an effect may be particularly true for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/63\">",
"       63",
"      </a>",
"      ], since this agent tends to be recommended to individuals with rheumatic diseases. The INR must be carefully monitored in patients taking these two drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"       \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiprothrombin antibodies &mdash; Antiprothrombin antibodies may result in prolongation of the prothrombin time (PT) even before administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . Such patients may present with bleeding as well as thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiprothrombin antibodies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H20#H20\">",
"       \"Acquired inhibitors of coagulation\", section on 'Prothrombin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variations in thromboplastin reagents &mdash; Some of the variation in the INR may be due to the use of different thromboplastins in the PT assay employed by different laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/62,64\">",
"       62,64",
"      </a>",
"      ]. One study determined the INR using eight different thromboplastin reagents in 43 patients with and 47 patients without lupus anticoagulants [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/64\">",
"       64",
"      </a>",
"      ]. Measurement of chromogenic factor X values, which are unaffected by aPL, was also assessed. A subset of six patients with lupus anticoagulants had widely varying results with one thromboplastin reagent (Innovin). In comparison, values of chromogenic factor X were identical between those with and without aPL.",
"     </li>",
"     <li>",
"      Effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      on coagulation factors &mdash; Warfarin primarily affects prothrombin, whose level is the most important determinant regarding the efficacy of warfarin [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/65\">",
"       65",
"      </a>",
"      ]. On the other hand, the INR reflects Factor VII levels much more so than prothrombin levels; Factor VII levels are not as affected by warfarin nearly as much as prothrombin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lupus anticoagulants may interfere with the accurate determination of the INR [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/65\">",
"       65",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The solution to this problem varies according to local expertise and practice. Possibilities include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Measurement of chromogenic factor X levels or the prothrombin-proconvertin time instead of the INR",
"     </li>",
"     <li>",
"      Measurement of F1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      F2 prothrombin fragment levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of thromboplastin reagents that provide varying results in the presence of aPL [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/62,64,66-68\">",
"       62,64,66-68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treating patients with LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or with lower dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in order to avoid the difficulties in maintaining a therapeutic INR [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Measuring Factor II (prothrombin) level to establish therapeutic depletion of Factor II and determine a patient-specific INR. In practice, this entails initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      treatment to a target INR of 2.0 to 3.0, then determination of the Factor II level. A 15 to 25 percent range is therapeutic; if the Factor II level is &gt;30 percent, the warfarin dose should be increased to a level that achieves therapeutic Factor II levels. Once a therapeutic Factor II level is achieved, the patient can be monitored by either Factor II levels or the corresponding INR [",
"      <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Self-monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-monitoring of anticoagulation using portable testing equipment at home is feasible for some patients. Such an approach may result in better control of the INR, especially for those with higher target INR values. Randomized trials have shown that appropriately trained patients who self-monitored and self-adjusted their oral anticoagulation had fewer thromboembolic events, fewer episodes of major bleeding, and a lower mortality compared with those undergoing standard monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=see_link&amp;anchor=H4#H4\">",
"     \"Outpatient management of oral anticoagulation\", section on 'Self-monitoring and self-management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation may be associated with a significant risk of bleeding complications. There are limited data on the risk of bleeding while on anticoagulant therapy for APS. In a retrospective study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation in 66 patients (approximately one-half of whom had primary APS and the others SLE), a target INR of 3.5 was selected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/70\">",
"     70",
"    </a>",
"    ]. Median follow-up in the cohort was five years. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four patients experienced major episodes of bleeding, but none resulted in death. Two retroperitoneal hemorrhages occurred in the setting of renal biopsies, and there were one large rectal bleed and one intracranial hemorrhage.",
"     </li>",
"     <li>",
"      Major bleeding and intracranial bleeding occurred at rates of 6 and 1.5 per 100 patient-years, respectively.",
"     </li>",
"     <li>",
"      Despite the relatively intensive anticoagulation target, six patients had recurrent thrombotic events (9 per 100 patient-years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed above, two randomized trials showed no significant difference in the occurrence of major bleeding episodes between the groups that received moderate- versus high-intensity anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Intensity of anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigational therapies for the APS include autologous stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/71\">",
"     71",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. To date, insufficient data on the use of these approaches exist to guide therapeutic recommendations.",
"   </p>",
"   <p>",
"    Some studies reported that glucocorticosteroids and other immunosuppressant therapies, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , could reduce the levels of aPL, and ongoing studies continue to explore this form of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/74\">",
"     74",
"    </a>",
"    ]. However, it is our and other people's experience that this form of therapy is rarely clinically effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with APS is dependent upon the clinical manifestations that lead to diagnosis. As an example, the prognosis is particularly poor during the initial episode of care when the patient presents with multisystem disease as seen in the catastrophic antiphospholipid syndrome (CAPS). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Catastrophic APS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The best data on morbidity and mortality are those from an international retrospective study of 1000 patients who were seen during the period of 1999 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/12/23754/abstract/75\">",
"     75",
"    </a>",
"    ]. The demographic characteristics of this group were as follow: 82 percent were female, 98.5 percent were Caucasian, the mean age at entry was 42 years, and 53 percent had primary APS (36 percent with SLE). Among these patients, 77 percent received treatment, 54 percent with oral anticoagulants and 45 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Of the patients enrolled, outcomes were determined in 85 percent. Morbidity and mortality were as follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent thrombotic or thromboembolic events occurred in 166 patients, these included strokes (n = 23), transient ischemic attacks (n = 23), deep vein thrombosis (n = 21), pulmonary embolism (n = 21), and myocardial infarction. Patients with thromboses or thromboembolic events had been receiving treatment with oral anticoagulants with a target INR of 2.0 to 3.0 (n = 90) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (n = 49), or were untreated (n = 27).",
"     </li>",
"     <li>",
"      Other morbid events included seizures (n = 17), heart valve thickening or dysfunction (n = 17), and microangiopathic hemolytic anemia (n = 9).",
"     </li>",
"     <li>",
"      Obstetrical outcomes in 77 women who had one or more pregnancies included live births (n = 63), preeclampsia or eclampsia (n = 8), early pregnancy loss (n = 18), premature birth (n = 28), and intrauterine growth retardation (n = 11).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality in this cohort was 5.3 percent. Causes of death included (in order of frequency) bacterial infection (n = 11), myocardial infarction (n = 10), stroke (n = 7), hemorrhage (n = 6), malignancy (n = 6), CAPS (n = 5), and pulmonary embolism (n = 6).",
"   </p>",
"   <p>",
"    In summary, patients who survive the initial episode that leads to the diagnosis of APS remain at risk for recurrent events. Currently available treatments (oral anticoagulation or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) may reduce, but do not eliminate, the risk of recurrent thrombotic, thromboembolic, or obstetrical adverse outcomes, and sometimes these events are fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Current therapies for the APS include the following medications (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Current therapies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      , including either low molecular weight heparin or unfractionated heparin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with SLE are also treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , which may have some benefit for patients at risk of APS. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hydroxychloroquine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial approach to thrombosis in the APS is identical to that of many other thromboses. For acute thrombotic events in patients with aPL, the first therapy is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . We recommend low molecular weight (LMW) heparin for most APS-associated thrombotic events (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      also plays a critical role in the treatment of the pregnant patient with the APS, because",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is contraindicated in pregnancy. Treatment of the pregnant APS patient is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\", section on 'Heparin/heparin with aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As with other thromboses, patients should be transitioned from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . We recommend an INR range between 2.0 and 3.0 rather than more intensive anticoagulation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Intensity of anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of anticoagulation for venous thromboembolic disease following a first event is uncertain. We recommend indefinite antithrombotic therapy in patients with definite APS and thrombosis, given the high likelihood of recurrence in the untreated patient and the potentially devastating nature of recurrent thromboembolic events (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with a first venous event, a known transient precipitating factor, and a nondiagnostic or low-risk aPL profile (an isolated, intermittently positive, low to medium titer anticardiolipin or anti-&beta;",
"      <sub>",
"       2",
"      </sub>",
"      GPI antibody), we suggest treating for a more defined period, such as three to six months. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Duration of warfarin use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of symptoms or a history of symptoms attributable to the APS, we do not recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      as prophylaxis in individuals with aPL alone and without systemic lupus or another systemic rheumatic disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with aPL and either SLE or related autoimmune systemic rheumatic disease but no APS manifestations, we suggest low-dose aspirin. Patients with SLE should also receive HCQ. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/1\">",
"      Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/2\">",
"      Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/3\">",
"      Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/4\">",
"      Boccalon H, Elias A, Chal&eacute; JJ, et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000; 160:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/5\">",
"      O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM 2000; 93:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/6\">",
"      Grau E, Tenias JM, Real E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001; 67:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/7\">",
"      Dunn A, Bioh D, Beran M, et al. Effect of intravenous heparin administration on duration of hospitalization. Mayo Clin Proc 2004; 79:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/8\">",
"      Douketis JD. Treatment of deep vein thrombosis: what factors determine appropriate treatment? Can Fam Physician 2005; 51:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/9\">",
"      Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/10\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/11\">",
"      Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/12\">",
"      Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/13\">",
"      Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/14\">",
"      Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/15\">",
"      Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/16\">",
"      Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep 2011; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/17\">",
"      Bick RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003; 17:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/18\">",
"      Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/19\">",
"      Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/20\">",
"      Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/21\">",
"      Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/22\">",
"      Mok MY, Chan EY, Fong DY, et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005; 32:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/23\">",
"      Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/24\">",
"      Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/25\">",
"      Espinola RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/26\">",
"      Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/27\">",
"      Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/28\">",
"      Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/29\">",
"      Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/30\">",
"      Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009; 68:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/31\">",
"      Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/32\">",
"      Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/33\">",
"      Alarc&oacute;n-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/34\">",
"      Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001; 44:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/35\">",
"      Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/36\">",
"      Ruiz-Irastorza G, Khamashta MA. The treatment of antiphospholipid syndrome: a harmonic contrast. Best Pract Res Clin Rheumatol 2007; 21:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/37\">",
"      Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/38\">",
"      Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/39\">",
"      Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 2002; 29:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/40\">",
"      Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/41\">",
"      Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/42\">",
"      Zavaleta NE, Montes RM, Soto ME, et al. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 2004; 31:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/43\">",
"      Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/44\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/45\">",
"      Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005; 14:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/46\">",
"      Leuzzi RA, Davis GH, Cowchock FS, et al. Management of immune thrombocytopenic purpura associated with the antiphospholipid antibody syndrome. Clin Exp Rheumatol 1997; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/47\">",
"      Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997; 81:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/48\">",
"      Kavanaugh A. Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med 1994; 121:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/49\">",
"      Alarc&oacute;n-Segovia D, S&aacute;nchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 1989; 16:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/50\">",
"      Durand JM, Lefevre P, Kaplanski G, et al. Correction of thrombocytopenia with dapsone in the primary antiphospholipid syndrome. J Rheumatol 1993; 20:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/51\">",
"      Suarez IM, Diaz RA, Aguayo Canela D, Pujol de la Llave E. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus 1996; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/52\">",
"      Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48:3320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/53\">",
"      Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/54\">",
"      Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/55\">",
"      Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/56\">",
"      Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/57\">",
"      Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003; 349:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/58\">",
"      Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/59\">",
"      Rubenstein E, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/60\">",
"      Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/61\">",
"      Zar T, Kaplan AA. Predictable removal of anticardiolipin antibody by therapeutic plasma exchange (TPE) in catastrophic antiphospholipid antibody syndrome (CAPS). Clin Nephrol 2008; 70:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/62\">",
"      Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/63\">",
"      Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/64\">",
"      Robert A, Le Querrec A, Delahousse B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe M&eacute;thodologie en H&eacute;mostase du Groupe d'Etudes sur l'H&eacute;mostases et la Thrombose. Thromb Haemost 1998; 80:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/65\">",
"      Kasthuri RS, Roubey RA. Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/66\">",
"      Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/67\">",
"      Douketis JD, Crowther MA, Julian JA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999; 82:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/68\">",
"      Tripodi A, Chantarangkul V, Clerici M, et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/69\">",
"      Lockshin MD. Antiphospholipid antibody. Babies, blood clots, biology. JAMA 1997; 277:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/70\">",
"      Ruiz-Irastorza G, Khamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/71\">",
"      Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005; 106:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/72\">",
"      Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/73\">",
"      Erkan D, Vega J, Ram&oacute;n G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/74\">",
"      Keswani SC, Chauhan N. Antiphospholipid syndrome. J R Soc Med 2002; 95:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/12/23754/abstract/75\">",
"      Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68:1428.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4682 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23754=[""].join("\n");
var outline_f23_12_23754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CURRENT THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30829462\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - SLE with aPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intensity of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2172855\">",
"      - Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Duration of warfarin use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Central nervous system manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other neuropsychiatric manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiac manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hematologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - TTP/HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Catastrophic APS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Therapeutic plasma exchange (TPE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Perioperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MONITORING ANTICOAGULATION WITH WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Problems in monitoring INR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Self-monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      COMPLICATIONS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      INVESTIGATIONAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4682|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/51/36667\" title=\"table 1\">",
"      Catastrophic APS criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35880?source=related_link\">",
"      Outpatient management of oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39322?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_12_23755="Antimicrobial therapy impetigo";
var content_f23_12_23755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antimicrobial therapy for impetigo (excluding MRSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adults",
"      </td>",
"      <td class=\"subtitle1\">",
"       Children*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Oral therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dicloxacillin",
"      </td>",
"      <td>",
"       500 mg orally every six hours",
"      </td>",
"      <td>",
"       &nbsp;25 mg/kg/day in 4 divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cephalexin",
"      </td>",
"      <td>",
"       500 mg orally every six hours",
"      </td>",
"      <td>",
"       &nbsp;25 mg/kg/day in 4 divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clindamycin&bull;",
"      </td>",
"      <td>",
"       300 mg orally every six hours",
"      </td>",
"      <td>",
"       &nbsp;15-25 mg/kg/day in 3 divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Erythromycin&Delta;",
"      </td>",
"      <td>",
"       250 mg orally every six hours",
"      </td>",
"      <td>",
"       &nbsp;40 mg/kg/day in 4 divided doses",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maximum single dose should not exceed dose for adults.",
"     <br>",
"      &bull; Note local prevalence of inducible clindamycin resistance; see text.",
"      <br>",
"       &Delta; Macrolides may not be adequate therapy given increasing resistance among S. pyogenes and S. aureus; note local resistance patterns.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23755=[""].join("\n");
var outline_f23_12_23755=null;
var title_f23_12_23756="Empiric antibiotics cellulitis";
var content_f23_12_23756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antimicrobial therapy for nonpurulent cellulitis (excluding MRSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adults",
"       </td>",
"       <td class=\"subtitle1\">",
"        Children age &gt;28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dicloxacillin",
"       </td>",
"       <td>",
"        500 mg orally every six hours",
"       </td>",
"       <td>",
"        25 to 50 mg/kg per day orally in four doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephalexin*",
"       </td>",
"       <td>",
"        500 mg orally every six hours",
"       </td>",
"       <td>",
"        25 to 50 mg/kg per day orally in three or four doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300 to 450 mg orally every six to eight hours",
"       </td>",
"       <td>",
"        20 to 30 mg/kg per day orally in four doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Intravenous therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefazolin*",
"       </td>",
"       <td>",
"        1 to 2 grams intravenously every eight hours",
"       </td>",
"       <td>",
"        100 mg/kg per day intravenously in three or four doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxacillin",
"       </td>",
"       <td>",
"        2 grams intravenously every four hours",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day intravenously in four or six doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nafcillin",
"       </td>",
"       <td>",
"        2 grams intravenously every four hours",
"       </td>",
"       <td>",
"        150 to 200 mg/kg per day intravenously in four or six doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        600 to 900 mg intravenously every eight hours",
"       </td>",
"       <td>",
"        25 to 40 mg/kg per day intravenously in three or four doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Table shows antibiotic selections for initial empirical treatment of infections not involving the face. Selection and/or dosing should be modified based on the results of culture and sensitivity testing. Pediatric dose should not exceed usual adult dose. If risk of MRSA, see \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\" for empirical treatment recommendations.",
"    <div class=\"footnotes\">",
"     MRSA: methicillin-resistant Staphylococcus aureus.",
"     <br/>",
"     * Dose alteration for renal insufficiency may be needed.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Alternate therapy for patients at risk of severe hypersensitivity reaction to penicillins and cephalosporins.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23756=[""].join("\n");
var outline_f23_12_23756=null;
var title_f23_12_23757="Late effects RT CT";
var content_f23_12_23757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of late effects chemotherapy and radiotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late effect of chemotherapy (agents)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late effect of radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone and soft tissues",
"       </td>",
"       <td>",
"        <p>",
"         Avascular necrosis",
"        </p>",
"        <p>",
"         (corticosteroids)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Short stature",
"        </p>",
"        <p>",
"         Atrophy",
"        </p>",
"        <p>",
"         Fibrosis",
"        </p>",
"        <p>",
"         Osteonecrosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        <p>",
"         Cardiomyopathy",
"        </p>",
"        <p>",
"         (anthracyclines, trastuzumab)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pericardial effusion",
"        </p>",
"        <p>",
"         Pericarditis",
"        </p>",
"        <p>",
"         Coronary artery disease",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        <p>",
"         Pulmonary fibrosis",
"        </p>",
"        <p>",
"         Interstitial pneumonitis",
"        </p>",
"        <p>",
"         (bleomycin)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pulmonary fibrosis",
"        </p>",
"        <p>",
"         Decreased lung volumes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        <p>",
"         Leukoencephalopathy",
"        </p>",
"        <p>",
"         (methotrexate)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neurocognitive impairment",
"        </p>",
"        <p>",
"         Radiation necrosis",
"        </p>",
"        <p>",
"         Second malignancies",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Peripheral nervous system",
"       </td>",
"       <td>",
"        <p>",
"         Peripheral neuropathy",
"        </p>",
"        <p>",
"         Hearing loss",
"        </p>",
"        <p>",
"         (cisplatin, taxanes, vinca alkaloids)",
"        </p>",
"       </td>",
"       <td>",
"        Brachial plexopathy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hematological",
"       </td>",
"       <td>",
"        <p>",
"         Myelodyplastic syndromes",
"        </p>",
"        <p>",
"         (alkylating agents)",
"        </p>",
"       </td>",
"       <td>",
"        Myelodysplasia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        <p>",
"         Decreased creatinine clearance",
"        </p>",
"        <p>",
"         (cisplatin, methotrexate)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Decreased creatinine clearance",
"        </p>",
"        <p>",
"         Hypertension",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Genitourinary",
"       </td>",
"       <td>",
"        <p>",
"         Bladder fibrosis",
"        </p>",
"        <p>",
"         Hemorrhagic cystitis",
"        </p>",
"        <p>",
"         Bladder cancer",
"        </p>",
"        <p>",
"         (cyclophosphamide)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bladder fibrosis",
"        </p>",
"        <p>",
"         Contractures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        <p>",
"         Abnormal liver function tests",
"        </p>",
"        <p>",
"         Hepatic fibrosis",
"        </p>",
"        <p>",
"         Cirrhosis",
"        </p>",
"        <p>",
"         (methotrexate)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Malabsorption",
"        </p>",
"        <p>",
"         Stricture",
"        </p>",
"        <p>",
"         Radiation proctitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pituitary",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        <p>",
"         Growth hormone deficiency",
"        </p>",
"        <p>",
"         Pituitary deficiency",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Thyroid",
"       </td>",
"       <td>",
"        <p>",
"         Hypothyroidism",
"        </p>",
"        <p>",
"         (sunitinib)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypothyroidism",
"        </p>",
"        <p>",
"         Nodules",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Gonadal",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Sterility",
"        </p>",
"        <p>",
"         (alkylating agents)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sterility",
"        </p>",
"        <p>",
"         Leydig cell dysfunction",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Sterility",
"        </p>",
"        <p>",
"         Premature menopause",
"        </p>",
"        <p>",
"         (alkylating agents)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Ovarian failure",
"        </p>",
"        <p>",
"         Early menopause",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Opthalmologic",
"       </td>",
"       <td>",
"        <p>",
"         Cataracts",
"        </p>",
"        <p>",
"         (steroids)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cataracts",
"        </p>",
"        <p>",
"         Retinopathy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23757=[""].join("\n");
var outline_f23_12_23757=null;
var title_f23_12_23758="Urea equilibration in HD";
var content_f23_12_23758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic figure demonstrating the relationship between urea clearance and equilibration when the access is parallel to the circulation in hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 271px; background-image: url(data:image/gif;base64,R0lGODlhtwEPAfcAAP///2bMmQAAADOZ/5nM//8zZv+Z/zMzmZmZmcDAwP+ZsxkzJoylmUBAQHK/mRAQEICAgDAwMODg4DNmTMwzmf/M/6CgoEyZcv+z/yYzP9DQ0PDw8LCwsD8mPyAgIH8ZM39/f2BgYFKlfFBQUHKZvwYMCSxZQs3m/7PZ/2az/3BwcOby/x8/L8zm/xMmHNjy5Uxmf0aMad/f37+/vz9/Xz8/PyZMOQwZE/+ZshlMfwwmP3ylz5CQkF+/j39Mf19/nw8PD78mTG9Cb5+fny+P76+vry8/T1myhQ8vT+/v7wYTH79yv898zyZyvx8fH185XzlyVhMZH0BAn2mMr0JZbxM5X7Oz2dns/xwmLz8MGR9fnxZCbwMJDwkMD09PTzlMXy8vLyNpr08vT2Zms19fX4+/7x8GDBxWj1Zyj9+F3yl8z59fn68jRg8DBi8cLw8JDyyF3yYmJpmZzNnZ7Iy48gwMJjNy2Nny5jOM8u+P729vb+bm801NpjNZvy8JE88pUkxZss/Pz4CAv1lsv6bS/69przOS+PPz+b/f///N2QkcLx8TH8DA308PH42NxnKS2Fms/zNSuP/m/wkJCV8TJo9Wj1lZrJ/P/zNmzIC//5kmct/v/7LY/02m/z9ZTDN/5f/5//zz+c85n28WLJ8fPzk8n/+f/98sWVJiuOXy/8Df/0xMTLnc/83N5m+JfPP5/3+l5SYJHDNMsszl/+8vX2yJ0nmShfuS+Pnm89lms2/CmV91xUCf/3V8eWZ/zNVGrP/f/9JNpoWv65LC+NtSuPWF62yyj+mm0//G/9Lp/6XS/48cOVkWQvWf7JlWg492j+yz2UZmVhMTE/X7+GYZTDMMJuVmzHNzuTOF60xyX6bT/+ty2O/A3//Z/4+Pj995k/zG+YKvmUJCQuaZzM9An/bZ7KzV/3O5/2lpadZZrPiM8rIshda5zIWy3+hs0v+m/3x8fHJycjNfxeKNxmnImf+5/8+2z/LN5gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC3AQ8BAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHkyYbCIFiBMrXsy4sePHkBcnKkzZrYICmDNr3sy5s+fPoDcrqExa7eXQqFOr/jy6tOuyp1fLng269evbYGPT3s3bNu7fW3XzHr7aN/DjVoUTX14bufPkzKOHNv68elPl0rMXoG69O1Ls2qNz//dOfij48MvHl1+/0oOFiOfRD1fPvr5JAQLcP8QhPzx9rxFoYN9X+OEXQQIN8ddfdv91hR8EAzpYIH4NIKiQgguKh1aBAUao1YQTNiAgQhhmmN6GE0Lo4VUgghiCDAeVaOJ8KE7Y4YpUtdgiGTASJGNqQQSB2SlBnGJig1zpKICKOEalZIsgJDHQj6jhh9kHAnywWxBZpobkVk/e2GRKEqgQwZNopqmmjkBECQCVoVlZAJZa0vJBFo2wgdkoWWRByR8FBPHBH6QEQYkAWWgZGpZrNuroo5AaqIIEF6XJ5JgkSRBCpJxC2iacoOH3wZ1d+tHGB34IAKgZH4zShhlzCv/QRpapmpEFaox2quuuj4ZAKUVqiokpSBY8wOuxSjoxBKiftTgooh8cqmUQfM4aq56Bdokrstx26+234LYYwaTAWRDuscoKxKxnctLJZaKjBsGGAHmmGquQ2Sq66Ln89uvvvxP6epu5AD9aQxE+0tZul220UegypNDJhhkC3IsZl3luW/DGOoaQwMcghywyyGqOMPLJKKes8soJQHBmgQ+8V5oExoYJAcs4h5xmAzMYtG5nC2v5RyP4mcEGLbVSbDFmWciK2jcf9ziRDDmjLPXUH7uM5gO/PoSmBxbWlEADE8pc2aZKVvjRkx6TOCNzX/Y0NtsRKfnApTdxULMAZhP/JoHdHITUcdcxvn0iU3orSThDOo6wOE4a1Mw1ZSro+MCIIE34gMAL/Wx4c01FrqMKEIEIdkEfbwB5zSFQ9rLmmGcuwN2qJ/g5jRslIKAGYa8kOogRlI7f3QZxgB/pOBmP3+N/6Ri4SBvQDpHnt3dGXSBe4AdGz143AADZLykPovCOH4S2BwOV2cAIgavPPgAJjNCACqpvoEIDDUBoP/54V0S2AMgbTIu8dxPqVU80BZEBEARABhCAAQQASMIMZnA1gmwgAX8j4EAuiEGCSKCDIvnfhB6ygdMdZAMCGMEIBBC46N0tBA1wIQRgaLwRVG4EAPDA3VSAPh1CgIcaSYCB/wrTot7RxIAHzIxx9CAACAoERhPSAwBqIAA9AGEGgdib98AHgAmRbgMi5IFIhDi+jJjLAuZqHQ/4JhAJrFFmElghBCDgAQEA4AGbgwCl8BgCPW7kZUS0UU6QmMTtFISK3BvIEJJQBCfYkYp6AIEMwCAAAQlgi3YEgAU2wIE6AgACAhBjAvr2kdfhRyNnisDLNgDKsLVyIGSb4xwBoIER1JFrtbwl8yYCykwKMEU5iU8hOWMcKiJsIEmgIhgWOEVfXlIgzwQfGAUQAWN9z5ck6WWBMqKBS87xTDzo5oEsMAJxjnIEazQZB1rXAAvMTQPtfGcQT0kYEBmRJsIcpmaMM/8EAYABRkUYAggEgDAqNnMgQEBfFzH5SRZeEwCbEtAFR0LGbWKkcs8zXvA48DIIcfRBn6xjCgGwwvy8p6T6mSc2A2PPYOpTNdShYoFAUAQBOIGSj/QlKCNQR4YazwOAjNwDGkC8MZYRK39bKWBAVLub5POlhjRIEUBAU4FMdQgCBUBWB2KBm0HgPV0VCAe+GlYAbKCrPGgqSJJq0azQ85dtdSpUURM3ohwVK28VzF1t8tSX1nUoe7VKXlk6QpfOFXROKuxHNgBDFdyPJoNdqmLleljWTCWwG9mUCizARZlEtnmT5WtlLVsREAwBIhK4GUowm5EE1FGPXOSA/MT4STH/phZBY92lRj7rF9bKpK/6VI8MZiClhAigBqjTrRD7JxLfXqRYl4SnHWtYOdKt8KwjreZIeNsX58LkMJEJr3jH+5jJHIQMBTrtDJoIgPWCQKYCmNv/3sNF8IW2uffdSH3teF0AaNdcsj0TCluH30DGdS81hSAVJche9wbCnzOYpgSih779AmCNbbtPfjViYQv/rXJpdGiB67nhuwy0Zyd2b3vZe1yBdDiT4FvuakuMEQuvEQI1FMiZHnBNAah1bUoF7YH10s/Tone4AvCCVlmM3IeWsMKV3MCZ4LekGQ9ZvzDOpAqMNYLapfPCI91ukHtL47okYZlUJEMEFyiABULQ/5E1kG8d36NNa/7tAcHT8JVzNObultnMAj0mAGRg2kCAoGeEhsA0uxq2rmqgrC2jbUm8CxXu8oXSlOlse3al0KdYei+YLkxZWVJRTt1zKZ/Oyx7qwGpWz2FYHClppHCYWL8cghFyGIMUDsDrXvdaCmNwBCMOAeuK0CxSk6v1XqxwDV87+9m+toQViF3siGjTUcxlSqrdIoddQ/vb0JaCHKhdbYeItFGdXsocrOCIMYzhAPjptbvlYIU9wKUVfAC3vr8tBUaU2yHrdVQikdIKQeTb2fGGNh8c8eq1WGHfEP+2HP7dkOytSclJscLBoZ1wcEs7LQ+PuMidPXGKK0SBav8CQgWHMgdL7Lvj+h5Dw8myB2+P/OYHmLnJDzLQNDnRKFawObhhrm8pWKEsjsC50gWxc4U48klOQErIIU70fft7LO9W+s2l0PSEBFxJAx9KzUVe9aLbWywEqIXWRV4LAnQ9IRZvEcaNIoiRl13fTEc7AQCx9n0DggBuf/tBUA4ilSNF6C8XAM75MBbA06EUff92KegAeMEjpOcT+nlRTjCASJBd8SOPxAAa7/hBRN7Zg6B85S1/kKfjJ+pI4bwdPn9zO4xe74AnAB1MH/nU5371rC/I1wUQdqJw3hC0H7khbh+W3/9eGI/YBd8hDohdPEIYzs998A9i8bkfhfMDwEP/H6gOeoj3AQ8DYD5Yss/+YcDiEb5ABSBQ4YtHwGIY7M/+9g2iQMMnBfzpJ376dne+dn7pl36kl38KuID5928v8IAvcAcSCIEUSIG90AsVmIES6BMAeIADgA12IA+ygHDl12uy0AeY8Ano54EIiHsM+IIMOBcBMIM0WIM2eIM4mIM6uIM82IM+OIM60YEseICG8Al2gAlIoAORgAl28AnLN4RDmIAwOIXsJ4M/eIVYmIVa2INBCIVe+IVg2ILNR4Vk6HxWuIVomIY7SA8O0IYOoAtX2IVhOIdzKIVlSIZnqIZ6uIcOgAB+iAAMEIc5IYR0WIgeaId3OIV5uIeMuIV9//iHgfiDcmiIlHiAiJiIL7iIjbiJP/iIfhiJPjiJlUiJl4iJC6iJnJiKOuiJgCiIOEGIo1iHLmiKmSgXqniLPMiKoMiFgxiLlVgSqfVVOkGLVIiKuHiMuuiKNwGLvviFJGEuQEVNPzYTxKiItniM2FiDySiJvdiMhTgSf+MBqoNhOFGNMGiM2ZiK2xiK3eiNshgSa4Q8KMRjN2GOtRgX6ZiO68iLr+iOdDgSoMQk27YS9hiD15iPyPiHrciN/eiPYTgS5kJr4tRjMSMTBXmKB4mQt7iPPCiKDgmFJHEmOHYmgYM//qVBL3GRCoiOGsmHCrmLHdmOHwmSESEsDMFYw//zPERFNs8DEyrZgBnZkpzIkTvokTN5iHVTkRGBRxxQkgdiSxb5k/oXlELZiESpg0Z5lGLoNfjRZRABXThkkiFAjz4plWZIlVXpkpCojDbBjEcpERPiAbEDEf+jlGVpltqHlmmphleZg1mplXAJItkmFHj5eyy5l1rYlzj4l29ZNwM0jYRZmMAHF4i5iYp5g4w5k4HZIg/Qk0QhmZP5FpVplS/JljXhljPJMWFCLi4BmoGHj6Oplp9omjSBmh+pmmnCOQQJmocZmz54mTaYmR9ZNSSjIxHAAcQJMloDM6R0EqB5Cb3pm7lYmgx5EyiglTQpPJojaRQxNwXSnCVRhjv/QALkuQNTiALRKZ2rSJ3sWI7YGYWOWSANoFsRkTj4AZ4jQYZUMCEZcJ7pqZ44CJw1OIzvyYKb2Zkd8TvJ5pxUKABdAAMQ+gP+qZcA2oMCSoMEWqCW6JghAJkY8TsExqBTGAUwcIfoSaEVuoMXCoQ5QQAauqEQYUIdEQr3MA7OUCDsgAsiCoNUkAHkSQLmCYMnCpspioUrGgAZ+qIxAQ25QAFOSgHVgB/MQAHBcAyhQBJkmAH8OaFEWqSdyJ78WI8vupUrEQpN+qROqgn4EQtPGgzlkJ9U+AMQGqFcSpleeoVHmqQa+hLpgKZoGgv4gabkoKMhAZpDaqd3+ptgGpPu/zmmLsENfoqm1BCoaDoPIjGFGbADPZoBnEoFdSqaiaqoa1mdNuGijtoS4PALkZqmlOqkotAMlwqDAkACWlog/Smk/3mnedqiY6p+KlEBt2ANohCpaioATyoKxYABsVqYhwqqoTqdo9qeYnqqLFEBBmAAt7ANxICm6xCov+AO6mAAylqoVLgDWDCrUYAGn+oWz2qhi1qUvEqtK2Gt11qv9nqv1zquIEGGWNAFXUACPbqubdGu0DqbpFoTpqqkLUGv+Nqw+bqssjoFPgoDt/qCzcquBLue0RqmpdqrLsGwDouv+voRZNgFaJABUxAFXyCwbJGxGmuw0tqx8vqr9yoEQv8QsuIKsS8IAxNCAiy7Fi6bg7vaqApbrff6BB2AsyPrEWV4skYwBVR4sQMbtDc4tNNatPN6r5XwBj7QtWsgsjrLgCRQBiaaq15qtTKLtTRrrx0wIUl7r0vbEVkqAF8AtVFrtkWKtghLh1qgBUSABFUwih97r0ywBIa7BEwAtuQ6hT9wrgKQrj+rFlRbte+KlfEahkpwBlWAH2fwiwuLr4XgA2ngA4kLt2H7gjugpRXLgFLbsvlIAwsQuwswgzHgAvjBAkeQhskou7E7gyLAAvjhAheApJcLhgLQBIqgA1ugA55rtPYqBPixBGLwBIq7r3HquCYbuWmBkBdgAwJwAxP/EAAxIAAlYAImcAPDi4bJiB+yGwBHUAICYAMT4ALhq6dfyAU5IAA5kAPMS4qfa69v8ARusAQ+8Lb2GrccMbd1S4atC7TcKwCzGwC2m7490AO6W5r4UYMmIADhO4O5a79euAX4gbyB67/OW68CsAQdsARIW70kS4VjW7YomooXAMEzmMGMuL4FMrsLIADpi6HF+4VEcAZhQAQ5oAbNm7Vs6waLIAYCUAkuzLSS2cCS+8ARjB8WLJutiB8TMAE0EAA9HAPBGcQhfMRcoAREkMRrW69M8Ab44QZ5EMVyO8V4m4Y1HMHeawMVDAUicMFricMzSAMC4AK5GwNfDMJQyAVa/4AEXMAFW6DGKQGy9Yq4DovAG2GodbyFNGC7JTC7R3ADE/LDiYnBEzKDPVwg9UvGUHi8SoAE/AvJKCHJNnuta3Czpru4eEnF25uPF9DFXTyDPUADXdzHfjybvvzLtNvFYky8RAuGray/ywvLJyHJbUu9BSzHCQyDnLrNnaq9aDG5Nqi3NJGwYHgGAsAFcKAEj2zCSlyvHeAGAtABQmDA9WrJGjGFOrK6C6jL3wzONCjO1FiIagAHRNAEaczOa3ytHeADS+DG9PywuGyWiJDJAArQMnEOdEgEy6sGSBAG0mwS1OwDBtDGD52zEc2AO2AE2+ypMNgCFK2e67jMlosTKf9Ah0gwwlWABB9dEpLMBGlwrWlQugd8ugrouPihzwro0jPcrusoACyQxYuZEzU9hwJwBjrQBK+M0JF8tKIbsvacEWQoAD8gAATwBSXa0i8tnU1NvjI9xjRNhwIQBletAzqt1bF8r20rAGLwtdh8yQ1KAlEAsEidf0rdpeC81rcL1UD81nNYBY2sBAKgBTtNEpJsAIXwBG78BkLw0/VM1PlHol+AH0YwhYWNqEI5Aap5A5gp1Rl9044suP9rr5fttkN90gu4AztQBkZgBGSL1kuNi6i9MU+92owdhmGQAwMAB0c82SNBzW+8BmlQy7VtvYwroWVY2s7qz2tdAm09oKz/PYdKgNwDQNfMLRKS/ASb7dWezX4qfYfYjbH+HABNPdx++d1heLzpl9WGOLg429f3HKeBXZ6knda+GdOMehNTjblVQAREoAglvN+xrSMl/dUYMbe2OuC/HaoWHRMJDob5WyBNUN4hwbAdUOImLs/+DdZxOqcwYN0v+N5TG98bDhMdDoZaQNceLeIgUdn9TeEXQYY/4LMEMAV2++IEHpsz/hI17oXHndzLbdfTTLhiYOK2PN0vjKlnHbC+bdiTm+QuseRQGN7pR95QDtL3Cs8FMuHr/Xsk0CKjveWmfdiVW9/FbbwhPgD6/Y2xfa0CsAYCYABPINK3TN0onQFdEAWc/2oEQWrkGZ6oXt4SYD6ESrDgDf7gen7CfL4Ei7AE85ziFR6nQk6GMO66Mj7nUV3nX/jhI6zjHyHJi+ADT4AfYuDpP06FZYAGc+riDDjqDlzqG3vgNhHpQ3jjHQ3bmD7STJAHYiAGcTzoV67NWwrn2S3nvw6vqD6HYdC5Zc7T/U3rFhHWWPCji77rRz6aj84Sws6Cyg3Z/QvhJ9wBTDDPVO7tFcGvZy3q5V6Z574S6T4ARHDjBaIEkr3tlI3CKkzbzi7FU0gFJEqn0g7f2m3qxI3gYfjh6ozfrO4RPK60a+58tXrUGM7lVLvvKtHv+SvwRIDxBN/c97oGJe4DzZ7wc/88heMp7iEf510u8W5N8WCoBo5dINq+8uZtr7FeIHBM7xRRhlMAA+0AA+O+gLxexb4OsxxbE/2efv+uA/jR7pfezkyg14VAwE+M9BOhn/hBAkawsg8f4xFf7TPN84UIB1tg6f8Y2z6wCESv5ratgF3wBeFOsTc/7Tnv9nQO93tq9/R8zTKfzfhMqyTwBYPNflG/y1O/kDFr9R5r9y2i94T+ghmABVFgBAKgrmtP6m1P9cCO+TO71dfqA5tP9hJBhjvQBfiBBb3N6CIftCSfElfvj/zd7Z299wsIpPje6Lqq89597dj5+8Bv0p2vgGNtt1Mg1lO4CfmOmLuPEr3qq6z/3/zO/+wLaARR8HuhP4UrcP17mf0nsf3MD/w+/u3avLqcav7on5bqbxLsv+fu3/GABxBGBOwgQGCHACMFFS5kuALAQ4gRJU6kWNHiRYwZNW68GMDjR5AhRXq8MMHkyQsCJoxk2dJlSAcIZCJg8BIkR5w5Lw7g2dPnT6BBhQ7QWdRiBQNJlS5lmhSD0Y0MpSokIUBAhgxWp0yd6hDqV7Bhw9p8OcHqWQE9Lhwh29ZmzJk124qlS3HoXbxB6xZF2tSv0qd7JXKd+qPLWRiEpXoV3NgxWLcuUy7wKGIBjQAXXFilrJlzgAUmPIYO0MOGVRY9yMKVKZfsY7p5ZeeFrbHv/1+/gR8rnkqCRBneDWsPJ94xMsvJJFUGKHHjQgwbzJ1DDyCAcnXKLErEgCJA9NuZNN0WhzrbvFDyFW/jZqrbcXD4vBmnpw/7OHLrylduvrEgRgD+/MPOo/wEKGGBBfIDL67x6sPpPAh9cjCi9dgDrLb4MuxqQg73um+k5DJb7ggobChBABFINBFFAVwgkLLmLpBRhNXCc82mDjWKcMccK7TQAPca03BIhebL8UidPhQpxJRWKsGGCVwo4Ygno5zyhhaxpMwE6yawgYUaGZwLSYt2jDBHYH5kChkMiRzSSDLjxEjJkCz7zjLMoEDQBhr1XIDPAERggYUYSAuABhYWIP80zNYalFMiMyE8Eph31DSlguHcfPNRTo2j81NQQWJNvDE7fSjS88TiwIOvuqkHt0tBIU5TDeE0tdNQcwV11BtfuvVUVGcDS4IGrAoLFEns6WDZZySRRNbiaM3Q1l/l1PXaD3l11NRghTVqAxXQEkuDB6x6QIL6pI2P2mrJxPZdt7QtldtuaSvKgnLFBYuDfAWwwEF14WO33SPhdUuEC3KNKR54SH3t13rtxSmBCNA666sEij3rX4ADlo9gUw1uK0GFERAgDodxhDjiu3CSIASL9eVIggQSgKDisx7guGOPCRsYZA4/EhS1QPnDDDQbErSBhhJKoNGEBcy6gUamUVP/LTQ9q77MTixp4NIF1SwzUDQ7N1vAGHEEmCQOV45gwSoXaGSpWpbvivluvPPWe28BQkCXw54V+xloBz+6YbsYXIzxbRrHNptLMBOkIYYWD6XhAi6hqM66BS7AcgIZBbhhghO/FEDzEly44LQYUhp9s2jIEECaVWx5u3UT5B6J7rqF4vt34PWOQIW/OwzcZ8IfVe47EVdqckCzEs6PZNAECFQ7q1ZSsHr9uG/S9QU2A325lDwxGWUGuDxwpZZ47x0onDTA+e7kKzqeq8HrJ68y7zw6QoT+UU5z+YnegKgnJekgbDnbo97zSNYkALJARmt5XvnOR5MeeA1Lmpvbyt73/xOdQABv+pvI/TZEwoJ5ZDMmMEEJAFQCK7GFgAKQHmUSNIG3iaZpE7jhgDySw9Yt54HL2QyUWDA+5wnAfJOYxCpcoSgcCuA/HbzVB+GnE/nFDIURMeFitpijj/TATyvpAdQABRrR0GABNCKN0qJWGQTxEDOGup5/8BQAqAXqMqXxE5/uaJlsIAAdcYiDLWKQqEW1z4NW5AlURCizLXZROF8MWq6oJzKXyOthVWRkT76SRWNRUpILyR8lHaOrPGIykzbaVqc66UmwPNKUoyySKSekSlx+RJMq4+QrxxWBWdKSAKW0pYdyiUtdMECZDAhHKzn1ykbSZQOiFCYxi0mXY/9m8z7u6+Q1wyLMYXozPdok57xcCU1xfgWc1kwnVMr5Tpdwk5HtNMo66TkceOZTJL96BTSJcs+cgBOgtdFnQT3CT38OFCesoCUrFPpQiLyAIxYrZkIhmpEr0PIKF32oRDdCUVtC4pWQ4ChGCWFCQmy0pAP1qEZAasorvFKlK73IFU7qsZTSVKHTmCgkRclIAuhUIyu4Qgs4oYwhmQMRyWCnUAf6UlsS4H2dQIFTdZKKTcwCEZy4hEIuwQlEzGITqbBqWSkCVVteQaT1oqpZwQICELhVrhVBazFPgAICpKATEIJEJrRxgrlCRQYCAEISAntYANS1nSdQBQEykQJe9IT/FynIBAFUAVjEfqUGVtFDZueqWIWG0rNiKQJaZDBas4L2qQJAbViS4AS0eKG1VlUtQEU726KAIGYzwK1Oa3vP2/aWI4ONWQ2Eu9Lf0jO4x83IZu9WBOZeNLntXG50K1JavDnBug+dbjqru92IvFZv3gCvbX0K0e+WFwC61Vth1Uvd83KXte+VCHH3Flf6erO74kwveDW2NyCcNr+2lMB+9TvfAXMgeCEYsC0TYOBr9je6G/BA8ASggQZT8sHxDS2C6fvI4DUgw18EsYTbWWAPqxfFFhZAAsBbBO0Wc34mTueGB/xfCwMzuoFwbjE3zGGA2pi+Cmbxxo67AdldzJY4/6axOGX5XgoX+SwemCZuedCvJreLyBC2Jc5GPJEZmwvDx01AhbVISXLFTMf1WRWHNrzmLz8kXDF7wJhnS6y8oRnLZ1FBffCc4vRorM9xhsiKLfYADrR2AyWm3xb5hbfiEWfRQK7NliNNaJjhrQEuziy++IbCjOWNweRZFZfDkua+EVoiEtizxSIAgZrZ2aoUAx7hZFCzm+ntXMX5s6k/ma9dqzoiFpBysY19bGQnW9nLZvbOYDPpEabn0VZxtrAfQmxmZ1vb2+Z2t5tNnFLnuTihNrK1J+Jpb6db3etmt7J1Npxei9sxNLPZjN9tboq8rN375ne//f1vgFvMb/i+iLIEVBDmgCdc4QtneMKHd2mCW3faexMuKPUWcYyHZQMj+PRxGX3mjIfcKBNv9HEtDnKRpxwnG2AypVH78SyrXOYPuXLJo3vymM9c5vHOOWIZrXOgb4QHvg6sxYN+dIwY/cM9R3rKn0xf+TVd6hWJeoOrPHWsZ13rW+d6173+dbCHXexjJ3vZzX52tKdd7Wtne9vd/na4x13uc6d73e1+d7znXe9753vf/f53wAde8INHe0AAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of standard hemodialysis in which flow through the access is in parallel with the systemic circulation. The degree to which urea is removed is dependent upon the rate of urea equilibration between intracellular stores (IC) and the extracellular fluid (EC). Slow equilibrators will have a lower BUN during dialysis but a slower rate of total urea removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23758=[""].join("\n");
var outline_f23_12_23758=null;
var title_f23_12_23759="Gang tattoos";
var content_f23_12_23759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common gang tattoos in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted courtesy of the American Medical Association",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_12_23759=[""].join("\n");
var outline_f23_12_23759=null;
